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Abstract 
 The Ras/Erk MAPK pathway has been shown to be important in multiple 
developmental contexts.  The development of T cells in the thymus is one such 
developmental system.  Thymocytes undergo positive and negative selection, processes 
by which they are “chosen” for their ability to recognize MHC molecules loaded with 
peptide on the surface of cells, but only to react when the peptide is foreign.  The Ras/Erk 
cascade has been shown to be indispensable during the onset of positive selection, but the 
mechanism of Erk signaling in this process is unknown.  In addition, it is unclear if the 
Ras/Erk cascade is involved in the differentiation phase of positive selection called 
CD4/CD8 lineage determination, where thymocytes either become CD4+ or CD8+ T cells.  
Furthermore, Erk signaling has been shown to be activated during negative selection, but 
seems dispensable.  In this thesis, we describe novel methods for analyzing Erk signaling 
by applying new technologies to gain a different perspective on Erk signaling in 
thymocytes during selection.  To this end, we have utilized a technique of intracellular 
staining to obtain data for single-cell Erk activation in the context of a population of fixed 
thymocytes.  We also pursued the development of FRET-based, genetically-encoded 
intracellular sensors of Erk activity that could be applied to the analysis of Erk signaling 
in live thymocytes in vivo.  To examine the involvement of Ras/Erk signaling during 
CD4/CD8 lineage determination, we applied a recently described method of lentiviral 
transgenesis to examine dose-dependent effects of a dominant negative form of Mek, the 
Erk MAPK kinase, in a single mouse generation.  These studies have yielded insights into 
Erk signaling events and advanced the development of novel techniques to examine 
signaling during thymocyte selection. 
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Chapter 1 
Introduction 
 
1.1  T Cells: An Overview of Development and Signaling 
 
1.1.1  T cells and the immune system 
The mammalian immune system is composed of two distinct parts, the innate and 
the adaptive.  While both parts are derived from the same progenitors, they serve distinct 
functions in the protection of the organism from outside invasion.  The innate immune 
system offers a first line of defense, where any breach of physical barriers (skin, mucosa) 
by pathogens immediately activates such players as polymorphonuclear leukocytes 
(neutrophils, basophils, eosinophils), monocytes/macrophages, and mast cells [1].  These 
cells are able to stifle many pathogens and, at a minimum, keep them at bay until the 
adaptive immune system has had sufficient time to mount a response.  The adaptive 
immune system, composed of T and B lymphocytes, then mounts a far more effective 
response, working in concert with the innate immune system to completely eliminate the 
pathogen altogether [2].  In this way, an individual can ward off infection and potential 
life-threatening illnesses.  Deficiencies in these processes often lead to chronic or 
opportunistic infections, which threaten the well-being of the organism. 
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T and B lymphocytes have the potential to recognize and eradicate any foreign 
pathogen.  The ability to accomplish this feat lies within the genetic coding sequence of 
the T cell receptor (TCR) and B cell receptor (BCR).  While the TCR and BCR have 
fundamental differences, they both possess a binding region that is derived from a semi-
random process called receptor rearrangement [3, 4].  This rearrangement is responsible 
for the ability of the adaptive immune system to generate cells that can potentially 
identify any foreign antigen a priori.  Of these two cell types, T cells are responsible for 
orchestrating the immune response, directing the other cells of the immune system to 
effectively respond to a foreign pathogen. 
As orchestrators of immune response, T cells must be able to distinguish “self” 
from “non-self” (i.e., foreign).  To achieve this end, T cells must be “educated” 
throughout their development to be able to scan Major Histocompatability Complex 
(MHC)-peptide molecules on antigen presenting cells (APCs) and react if foreign 
peptides are detected, but remain quiescent if only self-peptides are displayed [5-7].  
Portions of this education are stochastic in nature, such as receptor gene rearrangement, 
and other portions are seemingly instructive.  The end result of normal development is a 
repertoire of T cells, each with a unique receptor that will detect a unique foreign peptide 
antigen.  Faulty development can result in a multitude of disorders, ranging from the 
complete absence of T cells and therefore no effective adaptive immunity, to autoimmune 
diseases, when T cells become inappropriately activated by self-antigens and mount a 
response to host tissues [8, 9].  Either can be catastrophic, allowing infection that can lead 
to death or extensive damage to multiple organ systems, respectively. 
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1.1.2  Developmental path of the T cell 
T cells originate from hematopoietic stem cells (HSCs) in the bone marrow, just 
as all immune cells do.  T cell progenitors exit the bone marrow into the blood and home 
to the thymus, an organ located rostral to the heart.  The thymus has a distinct structure 
that plays a necessary role in the normal development of thymocytes [10, 11] (Figure 1-
1).  On the gross histological level, the thymus is separated into two distinct areas called 
the cortex and the medulla.  Aside from the T cell progenitors and thymocytes that 
occupy the thymus, the cortex is populated by epithelial cells and the medulla is 
populated by epithelial and bone marrow-derived cells.  These cells facilitate the 
developmental progression of thymocytes, providing distinct developmental signals [10].  
The spatial separation of these cell types is also functional, with the earliest 
developmental stages occurring in the outermost cortex (sub-capsular zone) and moving 
inward toward the medulla.  The progenitors mentioned above exit the bloodstream into 
the cortex of the thymus and are thus termed thymocytes until they exit into the 
bloodstream at the end of their development.   
At this stage thymocytes reside in the cortex and can be identified by surface 
markers termed clusters of differentiation (CD) 4 and CD8.  These cells are referred to as 
“double-negative” (DN) because of their lack of CD4 or CD8 TCR-coreceptor expression 
[12].  This population of thymocytes is usually characterized by 4 sub-populations, 
termed DN1, DN2, DN3, and DN4.  Each DN sub-population is identified by the 
expression pattern of two cell-surface markers, CD25 and CD44.  DN1 cells are CD25–
/CD44+, DN2 cells are CD25+/CD44+, DN3 are CD25+/CD44–, and the DN4 stage is 
CD25–/CD44– [13].  These phenotypic changes are used to follow developmental  
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Figure 1-1.  T cell development in the thymus.  T cell progenitors home to the thymus 
from the bone marrow and enter the thymic cortex.  As development progresses through 
the DN stages, cells move to the outer cortex and to the inner cortex and cortico-
medullary junctions at the DP stage.  Positive and negative selection ensue as thymocytes 
migrate into the medulla of the thymus.  Final maturation occurs in the medulla, and fully 
mature T cells migrate out of the thymus through blood vessels in the cortico-medullary 
junction.  Figure from [11]. 
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progress, but are not the only changes in gene expression of these cells. 
By the DN3 stage, there is a bifurcation that results in two different types of T 
cells that are characterized by the type of TCR chains expressed, either αβ or γδ [14].  
These two populations are functionally different and have different developmental paths, 
and the research we describe here is based on αβ T cell development.  In the αβ lineage, 
thymocytes have committed to the T cell lineage and begin to rearrange the TCRβ.  The 
TCRβ-receptor chain gene locus undergoes a series of recombination events, where small 
genetically variable regions of the gene are spliced together by RAG recombinases to 
form an intact receptor (reviewed in [15]).  Receptor rearrangement is also inaccurate at 
the site of gene splicing, which corresponds to the binding region of the translated 
receptor.  The variability produced by both the TCRα (discussed later) and β chains is the 
basis of foreign antigen recognition [16].  A consequence of generating this variability is 
that many rearrangements result in either an untranslatable gene product, which produces 
no receptor at all, or a translated receptor that is unable to recognize MHC molecules on 
the surface of target cells.  In the former case, the thymocyte has two gene copies and is 
able to rearrange both loci if necessary, giving the cell more than enough opportunity to 
produce a successfully translatable transcript.  The latter case is as useless to the immune 
system as no receptor at all, since the targets of the TCR are MHC molecules bound to 
peptides.  To achieve an acceptable level of variability within the T cell compartment, 
this process is incredibly wasteful.  It has been estimated that 90% of cells either do not 
successfully rearrange their receptor or successfully express a receptor that fails to 
interact with MHC-peptide on the surface of cortical and medullary APCs.  These cells 
fail to receive a signal from the TCR and end up dying by apoptosis [17]. 
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Upon rearrangement of the TCRβ chain gene locus that yields a full length 
receptor chain protein product, the TCRβ receptor chain is integrated into a complex 
containing an invariant pre-Tα chain and CD3, termed the pre-Tα receptor complex [18].  
The pre-Tα chain acts as a surrogate TCRα chain until the actual TCRα chain gene locus 
has been rearranged, which occurs later in development.  CD3 is made up of six receptor 
chains that form one homodimer (CD3ζζ) and two heterodimers (CD3δγ and CD3εγ) 
[19].  Under normal conditions both TCR chains and six CD3 chains form the TCR 
signaling complex, where CD3 is crucial in forming proper signaling events later in 
development.  This checkpoint, referred to as β-selection, is crucial in thymocyte 
development, and signals from this complex allow development to proceed.  The β-chain 
locus is prevented from undergoing further rearrangement by allelic exclusion, 
presumably to prevent further rearrangements on an already translatable receptor [20].  
Pre-Tα signals also induce cells to undergo several rounds of division and upregulate the 
coreceptors CD4 and CD8 [17].  We utilize co-expression of CD4 and CD8 as 
phenotypic markers indicating that the β-selection checkpoint has been passed and refer 
to these cells as double-positive (DP). 
The majority of DN development occurs in the cortex of the thymus (Figure 1-1) 
[21].  As thymocytes progress through the DN stages, they gradually move inward 
toward the medulla.  At the DP stage, they have moved through the cortex to the cortico-
medullary junction, where they begin to receive selection signals.  The process of 
selection is thought to be an “education” of thymocytes and is the basis for the ability of 
T cells to scan peptides loaded on MHC molecules, reacting to MHC bound to foreign 
peptides but not to self-peptides bound to MHC.  MHC molecules are expressed on the 
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surface of APCs and are loaded with peptides, derived from either intracellular proteins 
on MHC class I or extracellular proteins on MHC class II.  T cells must be capable of 
interacting with MHC/peptide complexes with enough affinity/avidity to scan them in the 
presence of peptide.  This interaction, however, must be weak enough to not elicit a 
response if only self-peptide is present.  A thymocyte with a TCR that binds MHC/self-
peptide with too high affinity/avidity could potentially react to tissues out in the 
periphery and cause auto-immune disease [9].  To this end, selection has been 
characterized by two processes, termed positive selection and negative selection. 
Positive selection is the survival and maturation of DPs due to intermediate 
affinity/avidity interactions between the TCR and MHC/peptides.  Phenotypically they 
are identified by the expression of CD69 and heat stable antigen (HSA) [22, 23].  Those 
cells that have TCRs that interact too weakly with or cannot bind MHC/peptide do not 
receive the proper intracellular signals to promote survival.  These cells then “die by 
neglect” meaning they apoptose due to the lack of signal.  Positive selection is counter-
balanced by negative selection, the process by which potentially auto-reactive 
thymocytes are removed from the T cell repertoire.  Thymocytes that recombine their 
TCR chains such that the receptor binds too strongly to MHC/self-peptide receive strong 
intracellular signals.  These thymocytes are deleted from the maturing population by 
apoptosis, avoiding the production of T cells that could possibly react to self [24, 25]. 
Positive selection also encompasses lineage determination, which is the 
maturation stage where thymocytes are driven to become either CD4 or CD8 “single-
positives” (SPs).  These cells complete their maturation in the medulla, where negative 
selection is strongest.  Expression of CD69 and HSA is down-regulated in these cells just 
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prior to exit, and phenotypically demarcate the most mature thymocytes.  It is estimated 
that only 5% of cells that begin development in the thymus reach this final mature stage 
[26, 27].  The cells exit through the same cortico-medullary blood vessels that they 
entered the thymus from, and enter the periphery as fully mature naïve T cells. 
 
1.1.3  Ras/Erk MAPK signaling in selection 
 The Ras/Erk MAPK sigaling pathway has been shown to be important in a 
multitude of different systems.  Many developmental processes require this cascade, such 
as eye development in Drosophila and vulval development in C. elegans [28, 29].  Ras is 
involved in the development of many cancers as well, indicative of the pivotal role the 
Ras/Erk cascade plays in normal cell cycle regulation, growth, and development [30].  
For a proper adaptive immune response to pathogens, intact Ras/Erk signaling is required 
for the activation of T cells [31].  Not surprisingly, signaling through this pathway is also 
required for proper T cell development in the thymus. 
 Ras signaling through Erk involves a multi-level kinase cascade.  Activated Ras, a 
21 kD small GTP-binding protein, recruits the MAP kinase kinase kinase (MAPKKK) 
Raf to the membrane.  Raf, in turn, phosphorylates and activates Mek, the MAP kinase 
kinase (MAPKK), which activates Erk MAPK.  Erk has many downstream targets that 
include Ets-family transcription factors, c-fos, and Egr1.  Erk also targets other kinases, 
such as ribosomal-S6-kinase, and targets some of the mediators of its own activation, 
such as the protein tyrosine kinase p56lck (Lck) and the membrane-bound adaptor 
molecule linker of activated T cells (LAT) [32, 33]. 
Analysis of the Erk-1 knockout mouse revealed a decrease in SP percentages, 
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indicating a deficit in positive selection [34].  However knockouts of H-Ras and N-Ras, 
yield no observed immune cell deficiency, and the K-Ras knockout results in embryonic 
lethality [35]. To side-step this difficulty, an effective way of studying the involvement of 
this pathway in selection has been the use of dominant negative forms of Ras (dnRas), 
Raf, and Mek (dMek1).  Under the direction of tissue-specific promoters that target 
expression to positively selecting thymocytes, transgenic mice expressing dnRas or 
dMek1 had severe blocks in positive selection [36-38].  When these transgenes were 
combined by cross-breeding, mice expressing both dnRas and dMek1 exhibited a 
complete block in positive selection.  Data from transgenic mouse studies using 
dominant-negative Raf also showed a deficit in positive selection in a transgenic TCR 
background [39].  It is important to note, however, that none of these dominant-negative 
signaling molecules alone are enough to completely block positive selection [37, 39].  
Data from transgenic mice expressing dnRas and a constitutively active from of Mek1 or 
the hypersensitive mutant Erksem did not show complete rescue of positive selection [40].  
These two sets of data reveal that other factors downstream of Ras are also involved in 
positive selection.  Other studies have looked at Erk signaling in selection using 
pharmacological inhibition of the Erk pathway.  The inhibitors PD98059 and UO126, 
which target Mek, inhibited positive selection consistent with transgenic data discussed 
above.  The results from some of these inhibitor studies, however, also implicated the 
Ras/Erk pathway in negative selection, which was inconsistent with data from transgenic 
mice expressing the dnRas and dMek [26, 41, 42].  Another study, however, did not see 
this effect [43]. 
One transgenic system that establishes Erk activation in the presence of negative 
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selecting stimulus involved the expression of a TCRα chain with the connecting-peptide 
motif mutated [44].  This not only established that differential signaling is induced by 
different components of the TCR/CD3 complex, but also that positively and negatively 
selecting stimuli yield of different Erk activation kinetics.  The negative selecting 
stimulus elicited a high level of Erk activation that was short-lived.  The positively 
selecting stimulus yielded Erk activation that was weaker, but of much longer duration.  
This may be indicative differential signaling kinetics similar to that seen in PC12 
activation with epidermal growth factor (EGF) and nerve growth factor (NGF) [45].  EGF 
stimulation of these cells stimulates proliferation, eliciting a strong but transient Erk 
activation.  NGF, however, stimulates differentiation of PC12 cells but yields a weaker 
activation of Erk that maintains itself over a long period of time.  This differential 
signaling has been linked to hyperphosphorylation of c-fos, increasing its lifetime and 
transcriptional activity.  This effect has recently been shown in mature T cells as well 
[46].  Further examination of transcriptional regulators activated by Erk changes overall 
gene expression during positive selection, and the feedback loops involved in Erk 
regulation may shed light on the mechanism of this differential signaling. 
 
1.1.4  CD4/CD8 lineage determination models 
 The onset of positive selection signals survival and maturation in DP thymocytes.   
In the latter stages of positive selection, DP thymocytes downregulate either CD4 or CD8 
coreceptor expression, in a process termed CD4/CD8 lineage determination.  In normal 
development, lineage determination is directed by the interaction of the TCR with MHC 
on thymic antigen presenting cells.  TCR interaction with MHC class II drives the 
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development of CD4+ T cells, whereas interaction with MHC class I drives CD8+ 
development.  Once the cell has made this determination, expression of the unwanted 
coreceptor is eliminated, and the cell enters the final stage of maturation as a single-
positive (SP) thymocyte before exiting into the periphery. 
Several models have been put forth in order to explain the mechanism of lineage 
determination.  The stochastic model states that the downregulation of either CD4 or CD8 
gene expression is a random event [47-49].  Once a DP thymocyte has received positive 
selection signals, it begins to downregulate one of the coreceptors.  If the incorrectly 
matched coreceptor is downregulated first, then the thymocyte continues maturation due 
to the signaling provided by the correctly matched coreceptor on the cell surface.  If the 
correctly matched coreceptor is downregulated initially, the cell lacks the proper signal 
because the unmatched coreceptor can not engage the TCR/MHC complex.  While the 
former situation induces survival and maturation, the latter results in death of the 
thymocyte due to the coreceptor/TCR mismatch.  For example, if a thymocyte bearing an 
MHC II-restricted TCR downregulates CD8, then CD4 remains on the cell surface and 
can provide signals for survival and further maturation.  If this same cell downregulates 
CD4, then the remaining CD8 molecules can not engage the TCR/MHC complex, and 
lack of signal causes the thymocyte to apoptose. 
Another model of CD4/CD8 lineage determination is an instructive model that 
states that lineage determination is driven by differential TCR/coreceptor signals.  In this 
model, the strength/duration of signaling drives maturation into either a CD4+ or CD8+ 
SP.  This model theorizes that strong/long duration signals elicit CD4+ maturation, and 
weak/short duration signals elicit CD8+.  Lck has been shown to bind to the intracellular 
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tail of CD4 with higher efficiency than CD8 [50], and therefore it is postulated that 
signaling initiated by CD4 is stronger than CD8.  It has also been shown in a two-step 
culture system that thymocytes expressing an MHC I-restricted TCR developed into 
CD8+ SPs with short duration signals, whereas longer duration signals caused these same 
cells to develop into CD4 SP thymocytes [51]. 
Yet a third model that has been recently proposed is the kinetic signaling model of 
CD4/CD8 lineage determination.  This model proposes that once positive selection has 
been initiated, thymocytes automatically downregulate CD8 coreceptor expression 
(reviewed in [52]).  The resultant CD4+CD8lo population then undergoes lineage 
determination by either the continuation or cessation of signaling.  If the TCR is MHC II-
restricted and requires CD4 coreceptor engagement or is coreceptor independent, 
signaling continues even though the CD8 coreceptor has been downregulated and results 
in the maturation of the thymocyte into a CD4 SP.  In contrast, should the TCR be MHC 
I-restricted and require CD8 coreceptor engagement, the cessation of signaling due to the 
loss of the CD8 would drive the silencing of CD4 and the re-expression of CD8.  This 
process has been termed coreceptor reversal, and the result is development of the 
thymocyte into a CD8 SP. 
 
1.1.4  Ras/Erk signaling in CD4/CD8 lineage determination 
 The involvement of signaling through the Ras/Erk MAPK pathway in fate choice 
of DPs is unclear.  Many of the investigations into lineage determination have 
concentrated on the protein tyrosine kinase Lck, which is a known activator of the 
Ras/Erk pathway.  Lck has been shown to bind to both CD4 and CD8 coreceptors, as 
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mentioned above, and is essential in initiating TCR signaling events that control β-
selection [53, 54] and positive selection [55-58].  Lck’s involvement in lineage 
determination has been suggested to differentially signal CD4 or CD8 development based 
on the strength of the signal elicited.  This is apparently due to the Lck’s preferential 
affinity for the cytoplasmic tail of CD4 over CD8.  The intracellular portion of CD4 binds 
to a far greater percentage of the Lck pool than does CD8 [50].  Mice expressing a 
chimeric transgene composed of the CD8 extracellular domain and CD4 cytoplasmic tail 
show favored development of CD4 in a MHC class I-restricted background [58, 59].  In 
addition, constitutively active and dominant negative mutants of Lck have been shown to 
direct CD4 development in a class I-restricted background and CD8 development in a 
class II-restricted background, respectively [55].  It should be noted, however, that Lck 
activation is pivotal in most downstream signaling elicited by the TCR and is by no 
means restricted to Ras/Erk activation. 
 Several studies have examined the role of Ras/Erk in lineage commitment directly 
by transgenic or pharmacological means.  In most of these studies, it was evident that 
dnRas and dMek affected the development of both CD4 and CD8 lineages equally [36-
38].  Only one study in mice expressing Erksem suggested that increased Erk activity 
improved the production of CD4 SPs [42].  In studies using PMA and ionomycin as 
pharmacological stimulators, DP thymocytes could be induced to develop into CD8 SPs 
with low dose/short duration stimulation and into CD4 SPs with high dose/long duration 
stimulation [60-62].  Conversely, pharmacological inhibition of the Ras/Erk pathway has 
shown a marked deficiency in the production of CD4 SPs but not CD8 SPs in FTOCs 
[41, 42, 63].  These latter studies, however, rely on pharmacological inhibitors that may 
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influence other signaling pathways and therefore may be the result of inhibition of 
parallel signaling pathways that are truly involved in lineage determination. 
 
1.2  FRET and Fluorescent Probes of Intracellular Signaling Activity 
1.2.1  Fluorescence resonance energy transfer 
 Fluorescence resonance energy transfer (FRET) is a phenomenon by which the 
dipoles of two fluorescent molecules interact, transferring energy from one to another.  
One fluorescent molecule, the donor, absorbs incident light energy consistent with its 
absorption spectrum.  The dipole of the donor influences the dipole of the second 
fluorescent molecule, termed the acceptor, transferring energy to the acceptor, which is 
given off as light energy in the emission spectrum of the acceptor.  An analogy of this 
process is the interaction of two tuning forks.  If one tuning fork is struck and placed 
closely to a second with similar resonance qualities, energy in the form of sound 
vibrations will transfer to the second fork and cause it to resonate.  It is important to note 
that this phenomenon is not the emission of a photon by the donor, which is then 
absorbed by the acceptor molecule, but rather a transfer of energy by dipole interactions. 
 Many factors determine whether or not FRET can occur between two fluorescent 
molecules.  The two most important factors are:  1) that the distance between the two 
molecules is 10-100Å and 2) that the emission spectrum of the donor and excitation 
spectrum of the acceptor overlaps.  The distance requirement poses some difficulty with 
the design and development of biomolecules tethered to fluorescent molecules if the 
minimum 100Å distance cannot be maintained.  On the other hand, this distance 
requirement allows for the detection of close molecular interactions with conventional 
 15
light microscopy, even though the interactions themselves are well beyond the theoretical 
resolution limit of the light microscope.  The latter spectral requirement is relatively easy 
to fulfill, due to the development of a vast number of small-molecule fluorescent 
compounds that can be chemically conjugated to many biomolecules and the 
development of spectrally shifted variants of green fluorescent protein (GFP).  Another, 
more minor factor affecting FRET efficiency is the angle between the dipoles of the two 
molecules.  FRET is most efficient when the dipoles are parallel and most inefficient 
when the dipoles are 90o to one another.  Other factors affecting FRET efficiency are the 
index of refraction of the medium and the fluorescence quantum yield of the donor 
fluorescent molecule. 
 
1.2.2  Sensors of intracellular signaling utilizing FRET 
 Some of the first applications of FRET to biological research involved the 
chemical conjugation of fluorescent molecules to biomolecules for proximity 
measurements [64, 65].  Since that time, a plethora of biological applications have been 
explored utilizing this phenomenon as a sensor of proximity and as a biomolecular ruler 
[66].  One application that has only recently been established is the use of FRET to study 
intracellular signaling events.  These studies have utilized the ease of molecular cloning 
and the development of spectral variants of GFP to create protein-based sensors of 
intracellular activity.  These sensors take advantage of fluorescence detection, which has 
become exquisitely sensitive with new technologies. Another key advantage is that these 
sensors are genetically encoded, allowing the easy delivery of these sensors into live cells 
to monitor intracellular signaling events taking place with spatial and temporal resolution. 
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 Some of the first developed sensors of intracellular activity were the “cameleon” 
sensors of intracellular calcium flux [67] (Figure 1-2).  These sensors were designed with 
two GFP variant pairs, either blue fluorescent protein (BFP) and GFP or cyan fluorescent 
protein (CFP) and yellow fluorescent protein (YFP).  These pairs were coupled together 
by a linker containing a portion of the C-terminus of the calcium-dependent binding 
protein calmodulin fused to the M13 peptide, the 26-residue calmodulin-binding peptide 
of myosin light-chain kinase.  The result was sensors capable of detecting the presence of 
Ca++ by an increase in FRET efficiency, due to the formation of a globular complex by 
calmodulin bound to Ca++ and the M13 peptide that brought the BFP/GFP or CFP/YFP 
into close proximity.  These sensors were not only active in in vitro analysis with the 
addition of Ca++, but also could be used to study calcium flux in HeLa cells.  Since the 
initial development of these sensors, they have been used for a myriad of studies, 
including calcium signaling in the endoplasmic reticulum [68], pancreatic β-cells [69], 
and zebrafish neurons [70]. 
 Many other FRET-based sensors of intracellular signaling have since been 
developed to look at other signaling events.  Sensors of caspase activity, for instance, 
allow real-time monitoring of apoptosis signaling [71, 72].  Pertinent to the topic of this 
thesis is the development of sensors sensitive to kinase activity.  Some have involved 
receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) and insulin 
receptor (IR) [73].  Quite a number of sensors of cytosolic kinases have also been 
developed, including sensors specific for protein kinases A and C [74-76], Abl, and Src 
[77].  To study small GTP-binding protein activity, sensors for Ras and Rap1 that are  
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Figure 1-2.  Cameleon sensors are Ca++-sensitive.  Fluorescent proteins linked by Ca++-
sensitive Calmodulin binding domain and the M13 peptide.  Upon Ca++ binding, 
orientation and distance between the fluorescent proteins changes, increasing energy 
transfer between the donor and acceptor molecules.  Figure from [67]. 
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active in cells have also been introduced [78]. This growing family of live-cell sensors 
will allow for the study of intracellular signaling dynamics that has thus far not been 
possible. 
 
1.3  Chapter Overview 
1.3.1  Chapter 2 
 Chapter 2 examines the mechanistic activation of the mitogen activated protein 
kinase (MAPK) extracellular-signal regulated kinases (Erk) 1 and 2 in thymocytes and 
peripheral T cells.  Erk activity is critical for DP cells to be positively selected, but their 
role in negative selection is still debatable.  Up to now, studies regarding Erk have relied 
mostly on the analysis of activation by western blot for activated Erk.  A caveat of this 
analysis is that it requires samples to be homogenized populations of cells to obtain 
enough protein for detection.  Erk activation, however, has been shown to act as an 
ultrasensitive switch in one system, meaning that once a threshold of activation has been 
reached, all the Erk MAPK in a given cell is activated.  Until that threshold is attained the 
entire cellular pool of Erk remains inactive.  This is a plausible mechanism for the “life or 
death” decision that DPs must make at that developmental checkpoint. 
 To be able to analyze DP thymocytes on a single cell level, we utilized a 
technique of intracellular staining followed by single-cell fluorescence detection using 
flow cytometry.  Using this method we were able to analyze single-cell phospho-Erk 
(pErk) levels and population dynamics under different time and dose conditions.  
Although we were limited to pharmacological stimulation of Erk using PMA, we were 
able to establish bimodal activation that occurs in a dose- and time-dependent manner.  
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Our data also suggested that strong activation signals led to a higher level of activation 
than under weaker stimulation conditions, and that the kinetics of activation were 
different with different dose levels.  This technique provided us with some insight into 
single-cell and population dynamics of Erk activation and could potentially lead to 
further understanding of Erk activation during positive and negative selection of 
thymocytes. 
 
1.3.2  Chapter 3 
 The technique of intracellular staining discussed in chapter 2 allowed us look at 
Erk activation under different stimulation conditions, but with the caveat that cells must 
be fixed and permeabilized prior to analysis.  This meant that Erk activation in 
thymocytes could not be monitored in live cells in real time.  To address this issue, we 
attempted to develop a fluorescent reporter of Erk activation utilizing the phenomenon of 
fluorescence resonance energy transfer (FRET) [79].  Using two variants of GFP 
connected by a peptide sensitive to Erk MAPK phosphorylation, we created a genetically 
encoded sensor of Erk activity.  CFP and YFP were used in conjunction with Erk-
sensitive peptides derived from the transcription factors Ets1 and Elk1.  Our proposed use 
of this reporter was to examine thymocytes undergoing selection and follow Erk 
activation in these cells using epifluorescence or confocal laser scanning microscopy. 
 Initial in vitro analysis of several constructs, which we named Erk Activity 
Sensors (EASs), yielded changes in FRET upon incubation with purified pErk.  It was 
evident from this data, however, that peptides derived from shorter sequences yielded 
maximal changes in FRET upon phosphorylation.  Further examination of the EAS-3 
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construct, which demonstrated the largest change in FRET, showed that the change in 
FRET was dependent on two consensus Erk phosphorylation sites and the MAPK binding 
domain.  This construct was also shown to be highly specific for Erk MAPK over two 
other prominent MAPKs, p38 and stress-activated protein kinase (SAPK; also known as 
Jun N-terminal kinase (JNK)).  The use of this construct in live cells, however, yielded no 
FRET change and was determined to be due to intracellular phosphatase activity.  We 
therefore were unable to utilize our developed sensor, in its current form, for in vivo 
analysis of thymocyte signaling during selection.  To address this difficulty, we have 
entered into a collaboration in an effort to derive a phospho-peptide specific binding 
domain by an mRNA-display selection process. 
 
1.3.3  Chapter 4 
 Our efforts turned to analyzing Erk signaling during CD4/CD8 lineage 
commitment stage of positive selection using the dominant negative form of Mek1 
(dMek1), the Erk MAPK kinase.  To this end, we utilized a new technique to create 
transgenic mice.  Recently, there was a report regarding the use of lentivirus as a delivery 
method of transgenes [80].  This method of transgenesis results in the generation of 
mouse litters in which each pup potentially carries a different copy number, ranging from 
0-30 copies.  Due to transgene delivery driven by viral mechanisms, integrations also 
occur throughout the genome and can potentiate the level of transgene expression.  The 
combinatorial effect is that each litter represents a dose response experiment, with 
transgene expression levels varying from mouse to mouse over a dose spectrum.  In 
addition, it was shown that transgenes delivered by lentiviruses can also be targeted to 
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certain tissues by tissue-specific promoters, including the Lck proximal promoter that 
directs expression to the thymus. 
 Before beginning our analysis of the effect of dMek1 on lineage determination we 
had to establish that transgene expression correlated with copy number and that the 
variegation in gene expression seen in the report above was stable.  We first showed that, 
indeed, the percentage of cells expressing the transgene and the overall level of 
fluorescence in thymocytes expressing a GFP transgene did correlate with copy number.  
We were then able to demonstrate that the variegation of transgene expression was stable 
using sorted transgenic thymocyte populations and by following their development in 
reaggregated fetal thymic organ culture (RgFTOC).  We then made mice using a 
lentiviral vector containing dMek1 followed by an internal ribosome entry site (IRES) 
and GFP, in a DO11.10 transgenic TCR background.  Our goal was to use GFP as a 
marker of transgene-expressing cells, but unfortunately GFP was not expressed even in 
thymocytes from a high copy number mouse.  Mice positive for the transgene did appear 
to have an effect on positive selection, but there was no effect on CD4/CD8 lineage 
decision.  We also tried over-expression of the transcription factor repressor of GATA to 
induce a lineage switch, but that too showed no effect.  Recapitulation of past transgenic 
experiments may be the key to circumventing the technical difficulties we have 
encountered with this method. 
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Chapter 2   
Intracellular Staining of Activated Erk MAP Kinase 
Reveals Switch-Like Activation Kinetics in Thymocytes 
 
2.1  Abstract 
 The importance of the Ras/Erk MAP Kinase signaling pathway in the positive 
selection of double-positive thymocytes has been established.  However, the mechanism 
by which Erk signaling conveys the signal to survive and mature is unknown.  In this 
chapter, we propose that Erk acts as an ultrasenstive “switch-like” mechanism where a 
threshold stimulus activates the entire intracellular pool of Erk.  To investigate the 
plausibility of this hypothesis, we utilized antibodies specific for the phosphorylated form 
of Erk and a method of fluorescence intracellular staining to analyze both single-cell and 
population Erk activation dynamics.  Pharmacological stimulation of Erk revealed 
bimodal activation of Erk in 16610D9 cells, primary thymocytes, and primary T cells.  
The Jurkat human T cell line, however, demonstrated a graded Erk response to increasing 
stimulus.  Our time-course analysis also revealed a quantitative effect on Erk activation 
that was dependent on the level of stimulation.  To further characterize subpopulations of 
thymocytes, rigorous optimization of cell surface marker staining for compatibility with 
intracellular staining protocols was performed.  These preliminary experiments have 
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provided us with insight into Erk activation dynamics that can be studied under more 
physiological conditions. 
 
2.2  Background 
 Cell-fate determination in any developmental context relies on the concerted 
action of extracellular stimuli and intracellular response [1-4].  Cells receive information 
from their surroundings through cell-cell contact and exocrine/paracrine factors, which 
direct the intracellular production of second messengers and activation of kinase 
cascades.  In turn, these complex responses elicit changes in gene expression that direct 
the developmental outcome of the cell.  In addition, cells express cell surface proteins and 
secrete factors that affect the developmental processes of surrounding cells.  In many 
tissues of the body, development terminates at the conclusion of sexual maturation, and 
cells enter a state of maintenance, with no further development.  Cells of the immune 
system, however, are constantly renewing themselves from sources of hematopoietic 
stem cells in the bone marrow.  The existence of countless parasitic organisms in the 
environment requires that the immune system be highly adaptable and also have an 
extremely high turnover (i.e., wasteful).  This “wastefulness” is not only a function of the 
actual immune response elicited by exogenous invaders, but is key to production of the T 
and B cell repertoires.  In the thymus, for instance, it is estimated that only about 5% of 
the thymic progenitors that enter the thymus successfully mature and exit the thymus as 
naïve T cells [5, 6].  There are several checkpoints during thymocyte development, such 
as β-selection, positive selection, and negative selection, which the cells must pass 
through to achieve maturation.  Failure at any one of these checkpoints results in death of 
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the thymocyte.  In a manner of speaking, the developmental outcome at each checkpoint 
is either life or death. 
 The process of positive selection, as discussed earlier, dictates this life or death 
outcome.  Insufficient engagement of the T cell receptor (TCR) with self-Major 
Histocompatibility Complex (MHC) causes “death by neglect” due to inadequate 
signaling downstream of the TCR [7-9].  The positively selected thymocyte can engage 
MHC bound to self-peptide, and the resulting signal triggers survival.  It has been shown 
that one of the necessary signaling pathways involved in positive selection is the Ras/Erk 
MAPK pathway [7, 10].  The mechanism by which the Ras/Erk pathway directs this 
process is unclear, however.  While much of the above data have suggested that Erk 
signaling is involved only in negative selection, there is also data to suggest that the 
strength and duration of Erk signaling can signal either survival by positive selection or 
death by negative selection [11]. 
 The dynamics of Erk activation during positive selection are unclear as well.  It is 
conceivable that Erk activation is a graded response, where strength and duration of 
signal dictate the percentage of intracellular Erk molecules that are activated and for how 
long.  This “rheostat” response would then rely heavily on downstream effectors and 
feedback mechanisms to determine the final qualitative developmental outcome.  Another 
possible mechanism of Erk activation is as an ultrasensitive, “switch-like” response.  In 
this scenario, the entire intracellular pool of Erk molecules would remain 
dephosphorylated until a threshold of activation is reached.  Once the signaling threshold 
is reached, the entire pool of Erk is activated.  This “all-or-none” response could mean 
the difference between life and death during positive selection. 
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 Evidence for ultrasensitivity in the Ras/Erk MAPK pathway comes from 
experiments conducted in Xenopus oocytes (Figure 2-1).  In 1998, Ferrell and Machleder 
demonstrated that Erk MAP Kinase acts as an all-or-none signaling member in 
maturation of Xenopus oocytes [12].  This is a departure from the long-believed 
mechanism that intensity of stimulus conveys intensity of signal.  Xenopus oocytes 
mature upon exposure to progesterone, where the oocytes move from a G2 arrest and 
progress to metaphase of meiosis II, where they arrest once again.   Intermediate stages of 
this transition are highly transient.  Once a threshold level of stimulus is achieved, all 
MAPK in the cell becomes phosphorylated, and maturation of the oocyte progresses.  
When examined on a single-cell basis by western blot, either >90% or <10% of MAPK in 
each cell was phosphorylated. 
This analysis utilizes the key advantage that Xenopus oocytes are extremely large 
single cells.  This offers the possibility of doing single-cell biochemical assays, such as 
western blotting in Figure 2-1B.  Since the threshold of progesterone stimulation is 
different for each oocyte, a study of MAPK activation across a homogenized population 
of oocytes would have indicated a combination of phosphorylated and dephosphorylated 
Erk.  To study these ultrasensitive systems it is necessary to be able to detect activation in 
a single cell and not in populations.  Therefore, examining the mechanism of Erk 
signaling in thymocytes poses a significant problem.  Thymocytes are in general quite 
small and have very little cytoplasm.  While antibodies for Erk and phospho-Erk (pErk) 
are quite robust, and western blotting is a relatively sensitive technique, the size and 
protein composition of thymocytes make single-cell analysis prohibitive.  To solve this 
problem, we have utilized a technique of intracellular staining using phospho-specific Erk  
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A
B
Figure 2-1.  All-or-none Erk response is triggered by threshold stimulation.  A)  The 
model of all-or-none versus graded activation responses suggests that Erk activation is 
either graded and increasing stimulus correlates positively to the percentage of Erk 
activated in a given cell (top panel) or that Erk activation is switch-like and requires 
threshold stimulus to activate (bottom panel).  B)  Single-cell western blots for MAPK 
reveal that Xenopus oocytes treated with progesterone are either fully activated or 
inactivated dependent on threshold stimulation.  As stimulus increases, a greater 
percentage of oocytes are fully activated.  Each lane corresponds to a single oocyte.  This 
figure was adapted from [12]. 
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antibodies and flow cytometry to study single cells over an entire population.  This has 
given us some insight into the mechanism of Erk activation in both thymocytes and 
peripheral T cells.   
 
2.3 Results and Discussion 
2.3.1 Intracellular staining of pErk reveals bimodal distribution of activation upon 
stimulation with PMA 
 To determine the efficacy of this approach, our initial experiments were 
conducted in the 16610D9 cell line.  These cells are similar to developing thymocytes, as 
they were derived from a CD4+/CD8+ double-positive (DP) murine thymoma [13].  While 
we concede that only guarded conclusions about in vivo mechanisms can be derived from 
a cell line such as this, these cells were a more appropriate starting point than other, more 
commonly used, cell lines such as NIH-3T3 or HEK-293 cells.  These latter cell lines are 
derived from connective tissue, and their developmental processes and intracellular 
signaling in response to extracellular stimulation are likely quite different than 
thymocytes. 
 16610D9 cells express abundant amounts of both the CD4 and CD8 coreceptor, 
but have very low levels of surface CD3 expression and do not respond well to α-CD3 
stimulation [14].  Therefore, we could not induce downstream Erk activation by cross-
linking CD3 using α-CD3 antibodies.  Instead, we used the phorbol ester phorbol-
myristate-12,13-acetate (PMA) as a pharmacological activator of the Ras/Erk pathway.  
PMA mimics the action of diacylglycerol (DAG), which is produced mainly by 
Phospholipase C-γ (PLC-γ), and usually activates the Erk pathway by binding to and 
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activating members of the Protein Kinase C (PKC) family [15, 16].  In thymocytes and T 
cells, however, the mode of activation is likely through the Ras guanine nucleotide 
exchange factor (RasGEF), RasGRP [17].  RasGRP has a regulatory DAG binding site, 
which PMA may bind to and facilitate activation.  Recent data, however, also suggests 
that RasGRP activation by PMA is mediated by a member of the PKC family, PKCδ, 
which is activated directly by PMA and activates RasGRP by phosphorylation [18].  
Once RasGRP is activated, it in turn activates small GTP binding proteins, such as Ras, 
and induces downstream Erk phosphorylation. 
 PMA is an extremely potent activator of Erk [19].  In thymocytes, full Erk 
activation can be accomplished with a 6 nM PMA treatment for 10 minutes at 37oC (data 
not shown).  Therefore, to analyze this activation it was necessary to perform a very tight 
dose response from no treatment to 6 nM PMA.  Canonical analysis of a homogenized 
population of 16610D9 cells by western blot reveals a dose-dependent increase in pErk 
that appeared to be a graded response to stimulation with PMA (Figure 2-2A).  With this 
method, increasing concentrations of PMA gave rise to positively correlative increases in 
total pErk protein.  In contrast, 16610D9 cells analyzed by flow cytometry demonstrated 
a bimodal distribution of pErk intracellular staining when doses of PMA were increased 
by 1 nM increments (Figure 2-2B).  At each successive dose there appeared to be a 
decrease in the number of cells in the “inactive” state and an increase in “activated” cells 
(arrows).  This illustrated the advantage of analyzing Erk on the single-cell level, rather 
than on the level of the entire population. 
The results obtained in 16610D9 cells prompted us to look at Erk activation 
dynamics in thymocytes.  Since we were particularly interested in Erk activation during  
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Figure 2-2. Differential analysis of 16610D9 cells stimulated with PMA reveals 
bimodal Erk activation.  A)  1 x 105 16610D9 cells were treated for 10 minutes with 
increasing amounts of PMA as indicated.  The cells were lysed and cytosolic fraction 
analyzed by western blot with α-pErk.  B)  16610D9 cells were treated with indicated 
amounts of PMA for 10 minutes, fixed with 2% formaldehyde, permeabilized with 
MeOH, and stained for pErk.  These two techniques illustrate the advantage of 
intracellular staining over western blotting of cell lysate.  By western blot, treatment 
appears to stimulate a graded Erk activation whereas bimodal activation is apparent by 
intracellular staining and analysis by flow cytometry. 
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positive selection, we used thymocytes derived from a C57Bl/6 MHC null (MHC-/-) 
mouse.  As previously discussed, thymocytes require TCR-MHC interactions to undergo 
selection and consequently arrest at the DP stage in an MHC-/- mouse.  These thymocytes 
were treated with very low doses of PMA, again due to the exquisite sensitivity of 
thymocytes to PMA.  We found that thymocytes were even more sensitive to Erk 
activation with PMA than 16610D9 cells, but showed a remarkably similar bimodal 
distribution with 1 nM PMA stimulation (Figure 2-3A).  Interestingly, the entire 
population of thymocytes treated with as little as 2 nM PMA showed maximal Erk 
activation, suggesting that the range of threshold of activation is quite narrow. 
 We were also interested in comparing the above data in 16610D9 cells and 
thymoytes with the Erk activation in peripheral T cells.  The threshold of Erk activation 
through TCR-MHC interaction is lower in DP thymoctyes than in naïve, peripheral T 
cells [20].  When we treated wild-type C57Bl/6 splenocytes with PMA, we found the 
same bimodal distribution of CD5+ cells with Erk in the inactive and active state (Figure 
2-3B).  Consistent with higher sensitivity found in DP thymocytes, peripheral cells 
needed at minimum 2 nM PMA for bimodal activation, and even 3 nM was not enough to 
activate the entire population. 
To gain perspective on these experiments with regard to human T cells, we treated 
Jurkat cells, which are human cells derived from an acute T cell lymphoma (Figure 2-4). 
We found a striking disparity with the results discussed in Figure 2-3.  With increasing 
PMA concentrations, there is an increased pErk staining of the entire population, with a 
positive correlation between the amount of staining and the treatment dose.  This pattern 
is indicative of the graded response, discussed above, with the percentage of Erk that is  
 41
 
0 nM PMA
1 nM PMA
2 nM PMA
3 nM PMA
pErk
# 
C
el
ls
0 nM PMA
1 nM PMA
1.5 nM PMA
2 nM PMA
3 nM PMA
A B
0
100
200
300
400
500
0
100
200
300
400
500
# 
C
el
ls
Figure 2-3.  Bimodal Erk activation occurs in both thymocytes and peripheral T 
cells.    A)  Thymocytes from an MHC-/- mouse were treated with indicated doses of 
PMA for 10 minutes.  Treatment with 1nM PMA obviously exhibits bimodal activation, 
indicating that threshold levels of PMA occur between 1 and 2 nM.  B)  CD5+
Splenocytes from a wt C57Bl/6 mouse also exhibited bimodal activation, with slightly 
higher threshold levels that was consistent with threshold of activation being higher in 
mature T cells than in DP thymocytes. 
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Figure 2-4.  Jurkats display graded Erk activation upon PMA stimulation.  As PMA 
dose increases, each cell activates an increasing percentage of intracellular Erk.  The 
result is a gradual peak shift of the entire population as dose increases, which is different 
than what is seen in 16610D9 cells, MHC-/- thymocytes, and wt splenocytes.  
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phosphorylated within the cell increasing as a function of increasing stimulation. 
 This final result raises some thought-provoking questions.  Is this graded response 
to stimulation in Jurkats a residual response that occurs in normal human T cells, 
indicating a fundamental difference in mouse versus human T cells and possibly 
thymocytes?  Jurkats are a transformed cell line that has been around since 1980 [21].  Is 
this result simply a byproduct of transformation and long term cell culture?  While testing 
Erk activation in human thymocytes presents a problem with obtaining tissue samples, 
the testing of human T cells extracted from whole blood is conceivable.  This, in 
conjunction with further characterization of the Erk response, could give us clues not 
only to the mechanism of Erk activation in thymocytes and T cells, but also to the 
differences between our mouse model and these processes in humans.  It is sometimes 
easy to lose the perspective that the final goal of these types of studies is to better 
understand human immunity and to use that understanding for the treatment of human 
disease. 
 
2.3.2 Bimodal Erk activation is a function of strength and duration of PMA 
stimulation 
 The above results gave us a starting point to understand and analyze Erk signaling 
under different conditions.  Two aspects we were particularly interested in exploring 
were the dynamics of strength and duration of stimulus, as well as how they affect 
downstream Erk activation.  It has been long debated as to how signal/duration of TCR 
engagement directs positive and negative selection and CD4/CD8 lineage determination, 
and which downstream players are responsible for the final developmental outcome [22].  
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While it has been argued that Erk signaling is involved only in positive selection and not 
in negative selection [7, 10], it has also been suggested that a short but strong TCR signal 
results in negative selection and a weaker but sustained signal yields positive selection 
[11]. 
 We looked at the levels of pErk in MHC-/- thymocytes treated with different levels 
of PMA over the course of several hours.  This gave us an opportunity to not only track 
the bimodality of Erk activation, but also gave us insight into the dynamics over time.  
Previously, it was shown by western blot that Erk would become activated quickly upon 
PMA stimulation, and then pErk levels would decrease to near pre-stimulation levels 
over the course of several hours [23].  Using intracellular staining of pErk allowed us to 
analyze single-cell levels of pErk over a period of time, giving us a glimpse at the 
kinetics of Erk activation, and to determine if the bimodal distribution of Erk activation 
was constant over several hours.  In addition, by following pErk over time at several dose  
levels, we could gain insight into the effects of weak and strong activation signals on the 
status of Erk activity in thymocytes.  
Our 10-minute dose response results in Figure 2-3 suggested that full activation 
Erk by PMA occurred over 0-3 nM.  We chose 5 different doses over this range and 
followed pErk levels at 10 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours.  We chose 
not to follow levels after 6 hours because thymocytes begin to die after a short time in 
culture without feeder-cell support.  The results showed that the status of Erk activation is 
dependent upon both the PMA treatment dose and the time of exposure (Figure 2-5).  At 
the low doses of 0.1 nM and 0.3 nM, activation of Erk only appears after 6 hours of 
treatment.  For 1 nM PMA treatment, bimodal distribution of Erk activation at 30 minutes  
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Figure 2-5.  Time course of thymocytes with different PMA concentrations reveals 
qualitative and quantitative differences in Erk activation.  At low PMA 
concentrations (0.1 and 0.3 nM), cells maintain a pool of inactive Erk until the 6-hour 
time-point, suggesting that duration of stimulation is important in Erk activation.  At 
higher PMA concentrations (1 and 3 nM), activation occurs much earlier, but a 
correlation remains between strength of signal and duration of signal to elicit Erk 
phosphorylation.  In addition, strong stimulation with 3 nM PMA elicits a 
“hyperactivation” of Erk at 10 minutes, which is reduced and maintained to the 3-hour 
time-point.  Eventually, Erk is completely deactivated, suggesting that a negative 
feedback loop is initiated once Erk is activated. 
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was evident.  At 1 hour, however, the entire population was activated, and this level of 
activation was observed up to 3 hours.  At 6 hours, all the cells in the population had pre-
stimulation levels of pErk, suggesting that the entire pool of Erk in each cell had been 
deactivated.  At the highest dose of PMA (3 nM) used in this time course, the pattern of 
activation was different than the other doses that were tested.  The initial reading taken at 
10 minutes showed higher peak fluorescence than at subsequent time points.  At 30 
minutes, levels of pErk dropped to an intermediate level of activation, and this level of 
activation was maintained at 1 hour and 3 hours.  As was seen with 1 nM treatment, pErk 
appeared completely deactivated by 6 hours. 
These results indicated that the threshold of stimulus for bimodal Erk activation 
could not only be dependent on dose, but also the duration of stimulus. This was 
particularly evident at the lower doses of 0.1 nM and 0.3 nM, where stimulation did not  
induce Erk activation until the 6-hour time-point.  In addition, the percentage of activated 
cells correlated positively with an increase in dose.  At 1 nM, Erk was activated in 
approximately two-thirds of the population at 30 minutes, but at 1 hour the entire 
population was activated.  These results suggested that weak activation signals are 
capable of initiating Erk activation if they are sustained.  Stronger signals, such as the 3 
nM treatment, induce a strong initial response, but the cell is then desensitized to further 
Erk activation. 
 The dynamics of Erk activation under the 3 nM PMA condition differed from 
lower doses in the early phase of activation.  The initial 10-minute post-stimulation 
staining had a high level of activation for the entire population of thymocytes.  At 30 
minutes, the peak had shifted to a lower level of fluorescence, indicating that there was 
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less pErk in the cells.  There is further shift, albeit slight, at 1 hour and the activation state 
maintains itself until 3 hours.  As with 1 nM treatment, levels of pErk had returned to 
basal levels by 6 hours.  It should be noted, however, that whole Erk intracellular staining 
was not performed in these experiments and would be a critical control in future studies. 
These changes in activation dynamics suggest a mechanism of Erk activation in 
positively selecting thymocytes.  On one hand, thymocytes could individually have a 
threshold level of activation, and the intracellular pool of Erk stays inactive until that 
threshold is reached.  Once a given cell has received an above-threshold signal through 
TCR/MHC interactions, a large percentage of the intracellular pool of Erk is activated in 
a switch-like manner.  Beyond this threshold, there may be a quantitative component to 
Erk activation, as observed in the 1 nM vs. 3 nM PMA treatments.  The 1 nM treatment 
yielded a moderate level of activation that was maintained and then shut off.  The 3 nM 
treatment yielded an initial pulse of higher activation that then fell to the lower level seen 
in the 1 nM treatment.  These observations are not only consistent with data that have 
suggested that differential Erk activation occurs with positively and negatively selecting 
signal [11], but also suggest a new component of the activation that may be the initial 
signal for survival in DP thymocytes undergoing positive selection. 
These preliminary experiments provided us with an overall picture of Erk 
activation in thymocytes and T cells with pharmacological stimulation, but did not 
distinguish the multitude of subpopulations within each tissue sample.  Thymocytes, in 
particular, have many developmental stages that are characterized by their surface 
staining, and our primary interest lies with DP thymocytes that are undergoing selection.  
To distinguish these subpopulations, cells are stained with multiple antibodies to selected 
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cell surface antigens.  Each of these antibodies is conjugated to a different fluorochrome 
and can be distinguished in a flow cytometer.  Analysis of these combinations is the long-
standing, canonical method of distinguishing subpopulations of immune cells. 
 
2.3.3 Optimizing cell surface marker staining under fixation and permeabilization 
conditions 
Intracellular staining of pErk requires fixation and permeabilization.  The 
permeabilization method we used to strip the cell membranes away required the use of 
methanol (MeOH).  MeOH fixation is very effective, but quite harsh and often results in 
the destruction of certain protein epitopes.  The proteins that are primarily affected are 
those that are associated with cellular membranes, including those cell surface markers 
that are usually used for subpopulation identification.  Therefore, it was necessary for us 
to optimize staining conditions for cell surface markers in conjunction with our fixation 
and permeabilization protocol. 
Subsets of thymocytes that are at different developmental stages can be 
characterized by cell surface staining of several different markers.  Examples of 
commonly used markers are CD4, CD8, TCRβ, CD25, CD44, and CD5.  In fact, the three 
main subsets of thymocytes are named for the surface expression of, or lack thereof, the 
TCR co-receptors CD4 and CD8.  Thymocytes negative for both CD4 and CD8, referred 
to as double-negative (DN) thymocytes, represent the earliest developmental subset and 
can be further subdivided by their surface expression of CD44 and CD25.  Early DN cells 
have not rearranged their TCR loci and therefore do not express TCRβ.  TCRβ 
expression initiates with β-selection, increases at the DP stage, and reaches a maximum 
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at the SP stage.  CD5 expression can be used to distinguish T cells from most B cells 
when analyzing the white blood cell (WBC) component from splenic extraction, as can 
TCRβ expression. 
We first tested splenocytes under three staining conditions:  1) antibody staining 
before fixation and permeabilization, 2) antibody staining after fixation, but before 
permeabilization, and 3) antibody staining after fixation and permeabilization.  For this 
initial test, we stained with α-CD5-PE, α-CD3-FITC, α-CD3-CyC, α-TCRβ-PE, and α- 
TCRβ-APC under the conditions mentioned above.  Our results indicate that the only 
effective condition for CD5 staining was to stain after both fixation and permeabilization 
(Figure 2-6A).  In contrast, CD3 staining was most effective prior to both fixation and 
permeabilization with the FITC conjugate (Figure 2-6B).  The α-CD3-CyC conjugate 
seemed to be ineffective under all conditions, with only a slight shoulder representing the 
CD3+ population in the sample stained before fixation and permeabilization.  TCRβ 
staining revealed effective staining both after fixation and permeabilization with the PE 
conjugate and before fixation with the APC conjugate (Figure 2-6C). 
 We also tested staining conditions for CD4 and CD8 in thymocytes, due to the 
importance of these markers in thymocyte analysis.  Staining condition 2 was eliminated 
because results in splenocytes indicated no real advantage of this staining condition over 
condition 1 or 3.  Two conjugates to α-CD4 and four conjugates to α-CD8 were tested 
(Figure 2-7).  α-CD4-PE was ineffective under all staining conditions, whereas staining 
with α-CD4-CyC prior to fixation/permeabilization gave a characteristic staining pattern 
of thymocytes from a wild-type C57Bl/6 mouse (Figure 2-7A).  For CD8 staining, all 
conjugates except for the PE conjugate were effective at staining before  
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Figure 2-6.  Optimizing surface staining under fixation/permeabilization conditions.
A)  Testing of α-CD5-PE conjugate.  B)  Testing of α-CD3-FITC and -CyC conjugates. 
C)  Testing of α-TCRβ-PE and -APC conjugates.  Splenocytes were stained under 3 
conditions:  1. antibody staining, followed by fixation and permeabilization, 2. fixation 
followed by staining and permeabilization, and 3. fixation and permeabilization followed 
by staining.  It is apparent that staining conditions are not only dependent on the 
antibody, but also the fluorescent conjugate.  For example, α-CD3-FITC stained under 
condition 2 gives robust staining, whereas the -CyC conjugate does not. 
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 Figure 2-7.  Optimizing CD4/CD8 staining under fixation/permeabilization
conditions.  A)  Testing of α-CD4-PE and -CyC conjugate.  B)  Testing of α-CD8-FITC,
-PE, -CyC, and -APC conjugates.  Thymocyte samples were stained under conditions 1
and 3 as described in Figure 6.  It is apparent that both the CD4 and CD8 epitopes are
destroyed upon permeabilization with MeOH, but can be stained prior to fixation and
permeabilization.  This data also suggests that PE does not survive permeabilization. 
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fixation/permeabilization, but not after (Figure 2-7B).  As with CD4, no staining 
condition with α-CD8-PE conjugate yielded the characteristic thymocyte staining pattern 
for CD8.  
 The results from Figures 2-6 and 2-7 provided some insight as to which cell 
surface marker epitopes are preserved during the fixation/permeabilization process.  This 
destruction is most likely due to the MeOH permeabilization step, as illustrated in Fig 2-
6B and 6C where staining conditions 1 and 2 gave similar results.  Fixation may play a 
role, however, as samples stained between fixation and permeabilization all show altered 
staining when compared with the other staining conditions.  It was apparent that CD4, 
CD8, and CD3 all required staining prior to fixation and permeabilization, presumably 
because the epitopes that their respective antibodies recognize were destroyed.  TCRβ, on 
the other hand, appeared to stain well after permeabilization with α-TCRβ-PE and prior 
to fixation with α-TCRβ-APC.  This would suggest that the TCRβ epitope is still 
accessible after MeOH treatment.  It is also clear from this data that PE can not withstand 
permeabilization with MeOH, as all PE signal was lost if staining was performed before 
fixation.  α-TCRβ- and α-CD5- PE conjugates were only effective if staining was 
performed after permeabilization, and α-CD4- and α-CD8- PE conjugates did not retain 
signal when the staining was done before fixation.  As such, we reserved PE for detection 
of pErk after permeabilization. 
 These experiments illustrate the importance of optimization of cell surface 
staining in conjunction with intracellular staining.  By no means have we covered the 
gamut of surface markers, and any future work in this area warrants the optimization of 
staining conditions prior to conducting complex experiments.  Testing of several different 
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conjugates to each antibody would be recommended, given that some conjugates (e.g., 
CD8-APC and TCRβ-APC) appear to give better staining than others. 
 
2.3.4 Cross-reactivity of cell surface marker antibodies with goat-anti-mouse 
secondary antibody used for detection of pErk intracellular staining 
The next logical step in our analysis of Erk activation in thymocytes was to 
initiate Erk signaling with a more physiologically relevant stimulus than PMA.  The 
simplest way to accomplish this is by ex vivo stimulation by cross-linking of the 
TCR/CD3 complex with α-CD3ε antibodies [24].  This simulates the aggregation of 
TCR/CD3 complexes when interacting with MHC molecules on the surface of an antigen 
presenting cell.  Thymocytes are incubated with α-CD3ε antibodies that are derived from 
Armenian hamster, which provides primary cross-linking of TCR/CD3 complexes.  To 
strengthen the aggregation, and thereby increase downstream signaling, α-armenian 
hamster secondary antibodies are used to cross-link the α-CD3ε.  However, we were 
using a biotinylated goat-anti-mouse (GαM-biotin) secondary antibody for our 
intracellular pErk staining, and we were concerned about cross-reactivity between this 
secondary and the α-CD3ε, as many commercially available anti-mouse antibodies cross-
react with armenian hamster. 
Most cell surface marker antibodies are commercially available, already 
conjugated to a variety of fluorochromes, and cross-reactivity is rarely an issue.  
However, our antibodies to pErk are not primarily used for immunohistochemistry and 
are not available directly conjugated to fluorescent molecules.  It is possible to purchase 
antibody labeling kits, but these are expensive, take time to optimize conjugation 
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conditions, and are rather inefficient.  The most efficient and economical method to 
detect pErk is using commercially available secondary antibody.  These antibodies can be 
purchased conjugated to fluorochromes for direct detection, or to biotin, for detection 
using streptavidin (SA) conjugated to a fluorochrome.  This latter method of detection is 
most effective because of the three-step signal amplification achieved by having a 
primary antibody specific for the intracellular target, multiple secondary antibodies 
recognizing each primary antibody, and several SA molecules binding to each secondary 
antibody.  Cross-reactivity of the secondary to a different target antibody, however, will 
result in the non-specific labeling with the fluorescent SA conjugate. 
We took wild-type thymocytes from a C57Bl/6 mouse and stained samples using 
various staining conditions (Figure 2-8).  Our results showed that the GαM-biotin 
secondary we were using for pErk staining was cross-reactive with the α-CD3 derived 
from armenian hamster.  Not surprisingly, when combined with pErk staining under 
stimulated and non-stimulated conditions, the fluorescence profile appears to be a 
combination of pErk and CD3 staining.  This led to further suspicion that other antibodies 
we would be using for surface staining would also be cross-reactive.  The TCRβ-chain 
antibodies at our disposal were also derived from armenian hamster, and the α-CD4 and 
α-CD8 conjugates were monoclonal antibodies derived from rat.  Rats are also closely 
related to mice, and antibody cross-reactivity is likely. 
We tested rat α-CD4-CyC, rat α-CD8-FITC, and armenian hamster α-TCRβ-
APC antibody conjugates with our GαM-biotin secondary antibody (Figure 2-9).  As 
with the α-CD3, all conjugates showed cross-reactivity, and pErk staining was befuddled.  
Our options at this point were limited to changing our pErk staining.  Many of the  
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 Figure 2-8.  GαM-bio secondary antibody used for pErk intracellular staining is
cross-reactive with α-CD3.  Unconjugated α-CD3 that is used for stimulations by cross-
linking TCR/CD3 complexes was tested with a biotinylated GαM secondary (2o) used for
intracellular staining.  Thymocytes stained with 2
o
 + SA-PE had limited background
staining (left panel).  When combined with α-CD3, cross-reactivity is evident by its
characteristic CD3 staining pattern.  Unstimulated and stimulated thymocytes were fixed
and permeabilized and stained with the combination of α-pErk, α-CD3, 2o, and SA-PE
(right panel).  The stimulated sample appears to be a combination of CD3 staining and
pErk staining. 
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Figure 2-9.  GαM-bio secondary antibody used for pErk intracellular staining also 
cross-reacts with α-CD4, α-CD8, and α-TCRβ.  A)  Similar to results with α-CD3, the 
GaM-bio 2
o
 cross-reacted with α-CD4-CyC, α-CD8-FITC, and α-TCRβ-APC (left 
panels).  The staining pattern was befuddled when samples were dual stained with α-
pErk and a surface marker antibody (α-(SM)) (right panels).  B)  Surface staining 
patterns were normal for each surface marker antibody in its respective fluorescence 
channel (FL-3 for α-CD4-CyC, FL-1 for α-CD8-FITC, and FL-4 for α-TCRβ-APC). 
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commercially available cell surface antibodies are derived from rat, mouse, and armenian 
hamster, and trying to avoid cross-reactivity by switching to different antibodies was 
prohibitive.  An unconjugated GαM could potentially have been used as a blocking 
agent, but would have been costly, added an extra step to an already long staining 
procedure, and may not have been as sensitive.  Our solution was to switch to a rabbit 
polyclonal antibody to pErk, and to test a biotinylated goat-anti-rabbit (GαR-biotin) 
secondary for cross-reactivity.  We again tested unconjugated α-CD3, α-CD4-CyC, α-
CD8-FITC, and α-TCRβ-APC.  Our results indicated that no cross-reactivity could be 
detected when secondary GαR-biotin and SA-PE were used in the absence of pErk 
antibody (Figure 2-10).  Dual staining of pErk and surface markers under untreated and 
treated conditions was comparable to pErk staining alone (Figure 2-10A, second 
column). 
 
2.3.5 Inability to activate thymocytes with α-CD3ε or Jurkats with α-hCD3 (OKT3) 
 As mentioned above, the next logical step in pursuing the analysis of Erk 
activation was to stimulate thymocytes and Jurkats by cross-linking TCR/CD3 
complexes.  Multiple trials were attempted to activate thymocytes with α-
CD3ε antibodies and Jurkats with OKT3, a monoclonal antibody to human CD3 [25].  In 
the thymocyte case, further CD3 cross-linking was provided by a secondary anti-
armenian hamster antibody.  In neither case were we able to elicit downstream Erk 
activation (data not shown).  This led us to pursue an alternative method for detecting Erk 
activation in live cells, which is the topic of the Chapter 3. 
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 Figure 2-10.  GαR-bio secondary antibody used for pErk intracellular staining 
shows no cross-reactivity with surface marker antibodies.  A)  Only background
staining was observed when thymocytes were surface-stained followed by biotinylated
GαR 2o antibody staining (left panels).  pErk staining under stimulated and unstimulated
conditions were all similar to the α-pErk staining only control (right panels).  B)  Surface
staining patterns were normal for each surface marker antibody in its respective
fluorescence channel (FL-3 for α-CD4-CyC, FL-1 for α-CD8-FITC, and FL-4 for α-
TCRβ-APC). 
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2.4 Future Directions 
Although we were unable to successfully stimulate thymocytes or Jurkats with α-
CD3, there are alternative methods of activating thymocytes in culture.  One option 
would be to use polymer beads that are pre-coated with α-CD3.  This would eliminate the 
need for a secondary cross-linking antibody because the polymer would keep the 
antibodies bound and clustered statically.  Another option would be to use a cell line such 
as P388D1, a transformed macrophage cell line that expresses Fc receptor [26].  These 
cells can effectively activate thymocytes when pre-incubated with α-CD3.  While these 
methods have been less used than canonical α-CD3 stimulation, they may provide a 
viable alternative. 
Another more physiological condition would be to utilize mice expressing a 
transgenic TCR to analyze Erk activation under more controlled conditions.  We would 
accomplish this by using physiologically relevant peptide presentation as the source of 
stimulation.  For example, the OT-1 transgenic TCR is MHC class I-restricted and 
specific for a peptide derived from ovalbumin [27].  Under normal developmental 
conditions OT-1 induces the development of CD8+ T cells, as well as in FTOC [27].  The 
agonist for this TCR is an octameric peptide with the amino acid sequence SIINFEKL, 
which induces negative selection of thymocytes.  A single-point mutation at position one 
of the peptide (S→E) produces a positively selecting peptide of the sequence EIINFEKL.  
Thymocytes could then be incubated with β2-microglobulin deficient (β2M-/-) antigen 
presenting cells that can be loaded with either of these peptides or in the absence of 
peptide to simulate non-selecting, positive-selecting, and negative-selecting conditions.  
Within the positive-selecting and negative-selecting conditions one can look at cell 
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viability with increasing peptide concentration.  Analysis of pErk by intracellular staining 
could give us clues as to Erk activation dynamics under positively and negatively 
selecting conditions. 
A more advanced approach may be to analyze Erk activation in thymocytes 
developing in fetal thymic organ cultures (FTOCs) using 2-photon confocal microscopy.  
Several groups have been able to track fluorescently labeled thymocytes in FTOCs using 
this microscopy technique [28].  For our purposes, we would only be able to analyze 
fixed and permeabilized samples, which may prove a technical challenge with the size 
and 3-dimensional structure of a reaggregated FTOC.  Penetration of formaldehyde, the 
fixation agent, may not be effective, and MeOH treatment of a reaggregated lobe might 
destroy the 3-D structure.  Staining might also prove difficult due to ineffective 
penetration of antibodies.  Regardless, it might prove useful and informative to visualize 
the Erk activation status of thymocytes in an environment that is similar to the thymus. 
 
2.5 Concluding Remarks 
We have established that Erk activation is switch-like with pharmacological 
stimulation.  This observation was dependent on using intracellular staining to analyze 
single-cell activation states.  The major drawback that this technique presents is that 
intracellular staining is most easily accomplished by cell fixation and permeabilization by 
stripping away the cell membrane.  This is the only way to provide access for the 
relatively large antibody specific for a given target.  While it is possible to gently 
permeabilize cells with saponin, thus avoiding fixation and harsh permeabilization but 
still allowing antibody entry, it is likely that this treatment would have a severe impact on 
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the homeostasis of the cell.  In addition, the introduction of a large macromolecule (i.e., 
an antibody) that binds pErk could present an artificial accumulation of phosphorylated 
Erk, due to the protection of the phospho-threonine and phospho-tyrosine of activated 
Erk from phosphatase activity.  This technique, while a useful method of looking at the 
activation status of Erk in individual cells, only provides static information from one 
point in time. To analyze Erk activation in real time, we looked to develop a sensor that 
could be introduced into cells and provide a spatiotemporal readout of Erk activity in 
developing thymocytes. 
 
2.6  Materials and Methods 
2.6.1  Materials 
 16610D9 (gift from Dr. C. Murre) and Jurkat (gift from Dr. J. Pomerantz) were 
cultured in complete RPMI medium (Invitrogen) supplemented with 10% v/v fetal calf 
serum (FCS) (Omega Scientific).  Thymocytes and erythrocyte-free spleen cell 
suspensions were harvested from 6-8 week-old adult mice from thymus and spleen, 
respectively.  Staining antibodies (BD-Pharmingen; eBiosciences) were used in various 
concentrations optimized for flow cytometry.  pErk antibodies (Cell Signaling 
Technology) were used at 1:200 v/v for intracellular staining and 1:2000 for western 
blotting.  Secondary GαM and GαR antibodies and streptavidin-conjugates were used at 
1:200 v/v for intracellular staining.  Secondary GαM antibodies conjugated to 
horseradish peroxidase (HRP) were used at a concentration of 1:10,000.  Enhanced 
Chemiluminescent (ECL) substrate (Amersham) was used for western blot detection. 
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2.6.2  In vitro stimulations and cell stainings 
 One million cells were resuspended in 175 µl of 1X Phosphate Buffered Solution 
(PBS) supplemented with 4% FCS (P4F) and indicated PMA concentrations.  After 10- 
minute incubation at 37oC, cells were fixed by adding 25 µl of 16% formaldehyde (Ted 
Pella) to each sample.  Samples were incubated again for 10 minutes at 37oC and 
transferred to flow cytometry tubes.  To permeabilize fixed cells, ice-cold MeOH (1.8 ml) 
was added to each sample tube while vortexing and samples were incubated on ice for 30 
minutes.  Samples were spun at 500 x g for 5 minutes, and the supernatant was removed 
and washed with 2 ml of P4F.  Samples were spun again as described above, the 
supernatant was removed, and samples were resuspended in 100 µl of P4F containing 
indicated antibodies.  Samples were incubated on ice for 15 minutes and washed with 2 
ml of P4F, and 100 µl of P4F containing secondary antibody was added.  Incubations and 
washes were repeated for streptavidin conjugates, and samples were resuspended in P4F 
for flow cytometry analysis.  Cell surface staining was performed in 100 µl P4F for 10 
minutes on ice either before fixation, between fixation and permeabilization, or after 
permeabilization steps described above.  Flow cytometry was conducted on either a 
FACScalibur or a FACScan (Becton Dickinson) and analyzed using Flowjo software 
(TreeStar).  All unlabeled axes are based on a log-scale relative fluorescence. 
 
2.6.3  Western blotting 
Whole-cell extracts were prepared from 1 x 105 cells, electrophoresed in 10% 
SDS-PAGE gels, and blotted onto nitrocellulose membranes.  All further described 
incubations were at room temperature.  Membranes were blocked in 5% skim milk in 
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PBS-T (0.05% Tween-20) for 1 hour and incubated in 1% milk/PBS-T with 1:2000 pErk 
antibody.  Membranes were washed 3 x 15 minutes with PBS-T and incubated with 
GaM-HRP secondary antibody for 1 hour.  Membranes were washed again as described 
above, incubated with ECL substrate for 5 minutes, and exposed to X-ray film. 
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Chapter 3 
Development of ERK Activity Sensor, an In Vitro, 
FRET-based Sensor of Extracellular Regulated Kinase 
Activity 
 
This chapter has previously appeared as:  Green HM, Alberola-Ila J: Development of 
ERK activity sensors, an in vitro, FRET-based sensor of extracellular 
regulated kinase activity. BMC Chem Biol 2005, 5(1):1.  The formatting of this 
paper has been adapted to this thesis, while content remains unchanged. 
 
3.1  Abstract 
Study of ERK activation has thus far relied on biochemical assays that are limited 
to the use of phospho-specific antibodies and radioactivity in vitro, and analysis of whole 
cell populations in vivo.  As with many systems, fluorescence resonance energy transfer 
(FRET) can be utilized to make highly sensitive detectors of molecular activity.  Here we 
introduce FRET-based ERK Activity Sensors, which utilize variants of Enhanced Green 
Fluorescent Protein fused by an ERK-specific peptide linker to detect ERK2 activity.  
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ERK Activity Sensors display varying changes in FRET upon phosphorylation by active 
ERK2 in vitro depending on the composition of ERK-specific peptide linker sequences 
derived from known in vivo ERK targets, Ets1 and Elk1.  Analysis of point mutations 
reveals specific residues involved in ERK binding and phosphorylation of ERK Activity 
Sensor 3.  ERK2 also shows high in vitro specificity for these sensors over two other 
major MAP Kinases, p38 and pSAPK/JNK.  EAS’s are a convenient, non-radioactive 
alternative to study ERK dynamics in vitro.  They can be utilized to study ERK activity 
in real-time.  This new technology can be applied to studying ERK kinetics in vitro, 
analysis of ERK activity in whole cell extracts, and high-throughput screening 
technologies. 
 
3.2  Background 
Traditional methods for studying signal transduction cascades have been based 
solely on biochemical analysis of whole cell populations and homogenized tissues (e.g., 
radioassays, western blots, etc.).  In addition, in vitro studies have required the use of 
radioactive isotopes for biochemical characterization of kinases.  These methods are time 
consuming, produce large quantities of radioactive waste, and do not allow for the study 
of real-time kinase dynamics. 
Recently, sensors for studying signal molecules in vitro, as well as cascade 
dynamics in single cells, have been developed utilizing fluorescent proteins and the 
phenomenon of fluorescence resonance energy transfer (FRET).  FRET is a phenomenon 
by which energy is transferred from one fluorescent molecule to another by way of 
dipole-dipole interactions during excitation of the donor molecule.  FRET efficiency is 
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given by the equation: 
 
1 + (R/Ro)6
1
=FRET efficiency
 
where R is the donor-acceptor radius and Ro is the radius at which FRET efficiency is 
50% (Förster radius).  Small changes in R (1-2Å) and small orientation changes between 
the donor and acceptor fluorophores can dramatically affect the efficiency of FRET, 
making very small changes in structure easily detectable.  The limitation, however, is that 
FRET is effective only between 10-100Å, and therefore the donor and acceptor must be 
maintained in close proximity.  Genetically encoded fluorescent proteins fused by linker 
peptide sequences have been utilized to address proximity limitations, as well as facilitate 
the delivery of the sensor into live cells. 
 Some of the earliest work done with these sensors includes genetically encoded 
sensors of caspase activity, in which caspase-3 and caspase-8 sensitive linker peptides 
were fused between the different variants of Enhanced Green Fluorescent Protein (EGFP) 
[1].  These studies allowed the characterization of apoptosis in single living cells with 
spatio-temporal resolution.  Other types of FRET signaling sensors have since evolved, 
including sensors for calcium signaling [2], receptor tyrosine kinases [3, 4], intracellular 
kinases [4-7], and histone methylation [8].  These sensors have been shown to be useful 
in in vitro assays, as well as to allow the study of signaling events in a single cell, in real 
time [4]. 
  The Ras/ERK cascade controls differentiation and proliferation in many different 
cell types and organisms. In this signal transduction pathway, activated Ras (Ras-GTP) 
binds directly to Raf-1 and recruits it to the membrane where Raf becomes activated. Raf 
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then phosphorylates and activates Mek-1 and Mek-2 (the MAPK kinase), which in turn 
phosphorylates the MAPKs ERK-1 and ERK-2.  Activated ERKs translocate to the 
nucleus and directly phosphorylate transcriptional regulatory proteins (including 
members of the Ets family of transcription factors, and the bZIP factors Fos and Jun) 
(reviewed in [9]).  Kinetics and in vivo dynamics of ERK MAP kinase activity are not 
completely understood.  Traditionally, the level of ERK activation has been thought to be 
relative to the strength of the upstream signal. Some data suggest, however, that ERK 
activation is “switch-like,” requiring a threshold of activation, above which all ERK 
molecules within the cell become activated [10].  Computational models of MAPK 
signaling mechanisms can fit both possibilities [11, 12].  Therefore, the development of 
new tools to study these dynamics is essential to determine the biochemical nature of 
ERK signaling.   
In this manuscript, we describe the development of several FRET-based sensors 
of MAP kinase activity, which we have called ERK Activity Sensors (EAS). Peptide 
linker sequences taken from the Ets family transcription family members Ets1 and Elk1, 
both ERK targets, were fused between cyan and yellow variants of EGFP (ECFP and 
EYFP, respectively).  Several of our constructs respond to phosphorylation by activated 
ERK with changes in FRET, and at least one of them, EAS-3, is specific for active 
Extracellular Regulated Kinase (ERK) as opposed to two other MAP kinases, p38 and 
SAPK/JNK. Therefore, EAS-3 is a viable, non-radioactive sensor of ERK MAPK activity 
in vitro. 
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3.3  Results and Discussion 
3.3.1  Design and model of EAS 
EAS was designed to have a short peptide linker sequence sensitive to 
phosphorylation by ERK fused between ECFP and EYFP.  ECFP and EYFP were chosen 
as a FRET pair because of the good spectral overlap between the emission of ECFP and 
the excitation of EYFP.  We hypothesized that phosphorylation would result in changes 
in secondary structure of the linker peptide that would alter FRET efficiency for the 
protein (Figure 3-1A).  Since it was unclear which factors would contribute to forming a 
suitable FRET sensor, we prepared several different constructs with peptide linker 
sequences containing ERK phosphorylation sites taken from Ets1 and Elk1 transcription 
factors, which are physiological substrates of the ERK MAPKs (Figure 3-1B).  EAS-2, 
derived from mouse Ets1, has a rather large linker peptide, due to the discovery that the 
MAP Kinase binding site (D-domain) is approximately 90 amino acids downstream of 
the target serine [13].  The linker sequences for EAS 3-5 were taken from human Elk1, 
which has been shown to have the DEF domain (FXFP amino-acid motif), a known 
MAPK binding site, near the C-terminus.  These peptides also contain two Serine-Proline 
(SP) motifs (consensus MAPK phosphorylation sites) corresponding to serines 383 and 
389 of Elk1, which have been shown to be targets of MAP kinases.  Phosphorylation of 
these serines has also been shown to be directed specifically by the DEF domain [14].  
EAS-Neg is a negative control construct with a short peptide linker derived from Ets1, 
containing a consensus MAPK phosphorylation site, but no MAPK binding site. 
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Decrease in FRET efficiency 
EYFP 
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EYFPEAS-Neg ECFP
ECFP EYFPmEts1 1-138 
EAS-3 ECFP
EAS-2 
hElk1 375-404 EYFP
mEts1 15-46 
EAS-4 ECFP EYFPhElk1 367-412 
EYFPEAS-5 ECFP hElk1 360-419 
 Figure 3-1.  A model for EAS activation and construct design.  See next page for
caption text.  
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Figure 3-1 cont’d.  (A)  Our inferred model indicates that upon pERK2 phosphorylation a 
conformational change in the linker peptide of EAS decreases the efficiency of FRET. 
The red area in the linker peptide indicates the relative position of either D-domain 
(EAS-2) or DEF domain (EAS-3, -4, -5), and the SP motifs denote the consensus 
phosphorylation sites.  (B)  The gene constructs include EAS-Neg and EAS-2, which are 
derived from mouse Ets1.  EAS 3-5 contain peptide linkers derived from human Elk1. 
The composition of each linker peptide is indicated by the primary sequence positions 
derived from Ets1 and Elk1, respectively. 
 
3.3.2  EAS FRET changes in the presence of active ERK2 
We expected a change in energy transfer between ECFP and EYFP upon 
incubation with active ERK2 (pERK2) for EAS to be effective as a real time sensor.  This 
would indicate that a phosphorylation event had affected the distance and orientation 
between the two fluorophores.  Each EAS construct was incubated with pERK2 in a 
fluorimeter (30°C), and readings were taken prior to addition of ATP.  Upon the addition 
of ATP, all EAS constructs, with the exception of EAS-Neg, showed a decrease of 
energy transfer indicated by an increase in donor (ECFP) emission (475 nm) with a 
concomitant decrease in acceptor (EYFP) emission (525 nm) after 40 minutes (Figure 3-
2A).  Therefore, a decrease in FRET efficiency correlates with phosphorylation of EAS 
by pERK2.  The resultant change in ECFP/EYFP emission ratio is comparable to or 
exceeds that of similar FRET-based signal transduction sensors [4-6].  Under the same 
conditions, EAS-Neg showed no change in FRET over the course of 30 minutes, 
confirming the specificity of ERK2 for EAS 2-5 and the requirement of a 
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phosphorylation event to induce a change in FRET.  Figure 3-2B shows the absolute 
change in ECFP/EYFP ratio over a 40-minute time course for each construct.  EAS-3 and 
EAS-4 show the greatest absolute decrease in EYFP/ECFP emission ratio, with EAS-5 
having an intermediate change in emission ratio.  EAS-2 showed very little change in 
FRET.   Phosphorylation was also confirmed by an in vitro kinase 32P phosphorylation 
assay using recombinant pERK2 (Figure 3-2C).  EAS 2-5 sensors were efficiently 
phosphorylated as compared to the non-specific control, EAS-Neg, and Myelin Basic 
Protein (MBP), a common target of activated MAPKs for in vitro studies.  Based on the 
robust FRET signal change and radioassay results, further studies focused on EAS-3. 
 
3.3.3  EAS changes in FRET in response to pERK2 require phosphorylation and the 
ERK binding site 
Mutants of EAS-3 were utilized to validate the structural features of EAS 
essential for decreased FRET efficiency upon incubation with pERK2.  We refined EAS-
3 by replacing the bulky N-terminal GST-purification tag (Glutathione-S-Transferase) 
with a Histidine-10 tag on the C-terminus.  This reduced the possibility that the large 
purification tag would interfere with FRET efficiency changes.  In addition, we mutated 
alanine 207 and alanine 487 to lysine.  As previously reported, this prevents EGFP 
dimerization [15].  This latter modification reduced co-purification of truncation products 
with full-length EAS (data not shown).   
To further characterize EAS-3, we generated different constructs targeting critical 
residues and analyzed their ability to serve as substrates for pERK2. Mutants EAS3-
S286A, EAS3-S292A, and the double mutant EAS3-S(286,292)A eliminated consensus  
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Figure 3-2.  EAS proteins are targets for ERK2 and exhibit decreased FRET 
efficiency upon phosphorylation.  (A)  Emission spectra indicate the effective FRET 
change for each EAS protein sensor.  Time course fluorimetry with EAS-Neg shows that 
pERK2 induces no FRET change 30 minutes after ATP addition.  All other EAS proteins 
show varying gains in ECFP emission (475 nm) and losses in EYFP emission (525 nm) 
40 minutes after ATP addition.  (B) Absolute change in the ratio of EYFP/ECFP 
emission for EAS-Neg is zero over a 30-minute time course, whereas a decrease in ratio 
for EAS-3, EAS-4, and EAS-5 is readily detectable at 2 minutes, and continues to decay 
exponentially over the time course.  EAS-2 has a detectable change in emission ratio, but 
the change is minimal as compared to other EAS proteins.  Error analysis was 
determined from three independent experiments.  (C)  EAS proteins (EAS-2, -3, -4, and -
5) are phosphorylated by pERK2 in the presence of γ-[32P]ATP.  This confirms that EAS 
proteins are targets of pERK2 as compared with MBP, a known ERK2 substrate.  As 
expected, EAS-Neg is not phosphorylated by pERK2. 
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phosphorylation sites (Figure 3-2A).  The dead binding domain mutant (EAS3-DBD) 
eliminated the DEF domain by replacing the two key phenylalanines with alanines, 
creating an AXAP motif (Figure 3-3A).  As Figure 3-3B demonstrates, all five mutants 
have decreased phosphorylation compared to the wild type sensor.  As expected, the 
EAS3-S(286,292)A mutant had the lowest level of phosphate incorporation due to 
absence of both serine-proline consensus phosphorylation sites required by MAP 
Kinases.  A decrease in phosphorylation of EAS-DBD is also consistent with the 
requirement of MAPKs to bind targets for efficient phosphorylation (reviewed in [16]).  
Differences between wild-type EAS-3 and mutants are also reflected in change of FRET 
efficiency when treated with pERK2 in fluorimeter experiments (Figure 3-3C).  These 
relative changes in FRET efficiency are consistent with the radioassay data. 
 
3.3.4  EAS-3 is not phosphorylated by pSAPK or pp38 
Distinguishing the activation of different MAP kinases within the cell is essential 
since each MAPK pathway is activated by multiple mitogens and external environmental 
factors to varying degrees (reviewed in [17]).  Furthermore, there is extensive cross-talk 
between the different MAP kinase pathways.  Detection methods must effectively isolate 
the signal of the target kinase from other family members to elucidate the contributions of 
these different pathways to a given cellular process. 
The target peptide linkers were designed to impart specificity for ERK.  Elk1 and 
Ets1 were chosen because of their seemingly specific interaction with ERK relative to 
p38 or SAPK/JNK (reviewed in [18]).  To determine whether EAS-3 acted as a specific 
substrate for ERK, we performed in vitro phosphorylation assays to quantify the ability of  
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Figure 3-3.  Mutation of key residues diminishes EAS-3 phosphorylation by 
pERK2.  (A)  Primary sequences of EAS-3 and EAS-3 mutant linker peptides are shown 
with consensus phosphorylation sites (highlighted in green) and ERK binding sites 
(underlined).  Residue mutations to alanine are highlighted in red.  (B) Analysis of 
mutant EAS-3 proteins by γ-[32P]ATP phosphorylation shows complete loss of pERK2 
phosphorylation of the S(286,292)A mutant as compared to wild-type EAS-3.  Decreased 
32P-phosphorylation of site-specific mutants also indicates the involvement of both 
Ser286 and Ser292 for pERK2 activity.  Requirement of the ERK binding domain for 
efficient phosphorylation is evident from decreased phosphorylation of the EAS3-DBD 
mutant.  Band intensities were quantitated by densitometry and are shown graphically. 
Equal protein loading is shown by Coomassie staining of EAS-3 and EAS-3 mutants, and 
phosphorylation assay was terminated after 15 minutes at 30oC.  (C) Fluorimetry data for 
EAS-3 and EAS-3 mutants reveal that the FRET efficiency change is reduced with 
various mutations, consistent with the phosphorylation assay in B. 
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pERK2, pp38, and pSAPK/JNK to phosphorylate EAS-3 (Figure 3-4).  As shown in 
Figure 3-4A, EAS-3 is an approximately 2000-fold more specific target for pERK2 than 
pp38, and 50-fold more specific for pERK2 than pSAPK/JNK.  Activities of pERK2, 
pp38, and pSAPK/JNK were confirmed by using known substrates specific for each 
kinase (Figure 3-4B).  MBP was used in conjuction with pERK2, GST-ATF2 with pp38, 
and GST-c-Jun with pSAPK/JNK.  Specificity of these kinases for EAS-3 was also 
confirmed by FRET in a fluorimeter (Figure 3-4C).  It is clear that the change in FRET 
was dramatic when EAS-3 was incubated with pERK2, but showed little or no response 
when incubated with pp38 or pSAPK/JNK.  This is consistent with the results found in 
4A. Given the similarity of these kinases, this also suggests that EAS-3 would be 
specifically acted upon by pERK2 even in the presence of other activated intracellular 
kinases. 
The demonstrated specificity of pERK2 for EAS-3 phosphorylation suggests that 
this sensor is a candidate for in vivo studies of ERK signaling.  However, our preliminary 
experiments in NIH-3T3 cells indicated that EAS-3 was susceptible to intracellular 
phosphatase activity (data not shown).  We surmise that this is due to the absence of a 
protective phospho-specific binding domain within the EAS-3 construct.  Such binding 
domains have been crucial in the development of other FRET-based signaling sensors of 
kinase activity [2-4,6,7].  These binding domains, however, are taken from naturally 
occurring domains that are specific for each target sequence.  Unfortunately, no known 
phospho-specific binding domain exists for Elk1 in the region of Ser383/389.  Therefore, 
we are using a semi-rational approach to develop a phospho-specific binding domain that 
acts to protect the phosphorylated EAS-3 linker from intracellular phosphatases.  This  
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Figure 3-4.  Determination of ERK2 specificity for EAS-3.  (A)  Phosphorylation of 
EAS-3 is efficient with pERK2, but not pp38 or pSAPK.  pp38 and pSAPK incorporate
little or no 32P into EAS-3 at the same relative specific activity as pERK2.  Band 
intensities were quantitated by densitometry and are shown graphically.  Equal protein 
loading of EAS-3 is shown by Coomassie staining.  (B)  Specific targets for pERK2 
(MBP), pp38 (GST-ATF2), and pSAPK (GST-cJun) are efficiently phosphorylated in the 
presence of γ-[32P]ATP.  The amounts of active kinase used in A were based on the 
relative incorporation of 32P into each cognate substrate by the respective kinase.  (C)
Fluorimetry of EAS-3 with MAPKs shows that the FRET efficiency change is 
significantly diminished in the presence of pp38 or pSAPK as compared to pERK2.  This 
is consistent with the phosphorylation assay in A. 
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will enable us to adapt the EAS-3 sensor for use in live cells. 
 
3.4  Conclusions 
 These results show that our novel ERK Activity Sensors provide real-time in vitro 
detection of MAP kinase activity. This method can be applied to studying kinetics of 
ERK activity in real time, as well as detection of ERK activity in unknown cell lysate 
fractions. There is also the potential to use these sensors for high-throughput screening of 
ERK kinase activity with fluorescence plate readers.  This method is more direct and 
convenient to monitor ERK activation in vitro than conventional assays that either use 
radioactivity for detection or rely on indirect detection using phospho-specific antibodies 
for MAPK targets. 
 
3.5  Methods 
3.5.1  EAS constructs 
 DNA coding for peptide linkers was amplified by PCR with primers designed 
with Bgl II and BamHI sites at the 5’ and 3’ ends, respectively.  The products were 
cloned into pECFP-C1 (Clontech), and EYFP from pEYFP-N1 was subsequently cloned 
in frame to create EAS constructs.   EAS’s were cloned into pGEX-2T (Amersham) in 
frame with GST for expression and purification purposes.  These GST-tagged constructs 
were used for initial fluorimetry experiment of EAS constructs.  Other versions of EAS’s 
were constructed using ECFP and EYFP with mutation A(207,487)K, which eliminates 
dimerization of GFPs, and cloned into pET21a (Novagen) with a Histidine-10 tag.  These 
His10-tagged constructs were used for mutant and specificity experiments.  EAS-3 linker 
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mutants were made by Quickchange Site Directed Mutagenesis (Stratagene) to make 
either single or double point mutation within the peptide linker.  For expression in NIH-
3T3 cells, EAS’s were cloned into the pECFP vector backbone without tags. 
 
3.5.2  EAS and active kinase expression 
 BL21(DE3) cells were transformed with EAS constructs and plated on LB agar 
supplemented with 100g/ml ampicillin.  Colonies were picked into 4ml LB-Amp and 
shaken overnight at 30oC.  250ml LB was inoculated with starter culture, grown to A600 
of 0.6, and induced with 0.1mM IPTG for 18 hours.  Cells were spun down, lysed by 
French press, and cell fragments were spun down at 18,000 rpm in a Beckman JA-20 
rotor for 30 minutes.  Proteins were purified from lysates over Ni-NTA Superflow 
(Qiagen) or Glutathione Sepharose 4B (Amersham).   
Activated kinases were purified as described [19].  pERK2 was either purchased 
(NEB) or purified from bacteria transformed with a plasmid containing both 
constitutively active MEK1* and His-tagged ERK2.  Phosphorylation of ERK2 by 
MEK1* occurred in bacteria prior to lysis.  BL21(DE3) cells were electroporated with 
MEK1*/ERK2 construct and grown overnight at 37oC on LB-Amp agar plates.  Several 
colonies were picked and incubated in 4ml of TB supplemented with 100g/ml 
carbenicillin.  The starter culture was added to 1L of TB, grown to A600 of 0.35, and then 
induced with 0.25mM IPTG for 12 hours at 30oC.  Cells were harvested and lysed as 
above and purified over Ni-NTA Superflow.  Activated p38 and SAPK/JNK were 
purified from bacteria electroporated with two plasmids, one coding for constitutively 
active MEK kinase 4 (MEKK4*) and another coding for MEK4 and either His-tagged 
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p38 or His-tagged SAPK/JNK.  These constructs were grown and purified as above, 
except with both carbenicillin and kanamycin (50g/ml).  Protein concentration and 
buffer exchange performed with Centriplus, Centricon, and Microcon ultrafiltration 
membranes (Millipore). 
 
3.5.3  Kinase assays and fluorimetry 
 Radioactive kinase assays were performed in 25 µl in 12.5 mM MOPS pH 7.5, 
12.5 mM β-glycerophosphate pH 7.3, 7.5 mM MgCl2, 500 µM NaOrthovanadate, 500 
µM NaF, and 9.7 nM DTT.  Amounts of kinase and substrate added to reactions are 
indicated in figure legends.  Finally, ATP supplemented with 0.2 nmol [γ-32P]ATP (6000 
mCi/mmol, Molecular Bioproducts) was added to a final concentration of 1 mM.  
Reactions were incubated at 30oC for 15 minutes, 8.3 µl of 4x protein sample buffer (SB) 
were added, and samples were boiled for 5 minutes.  Samples were analyzed with 10% or 
12% SDS-PAGE (BioRad Mini-Protean II) and transferred to a nitrocellulose membrane.  
The membrane was exposed to a phosphoscreen and scanned on a Storm 860 (Molecular 
Dynamics).  Quantitative densitometry of bands was performed using ImageQuant 5.0 
(Molecular Dynamics).   
Fluorimetry was performed in a Shimadzu Spectrofluorophotometer RF-5301PC. 
Assays were performed in same buffer as above in a volume of 2.5 ml.  The final 
concentration of EAS constructs was 250 nM, and final concentration of pERK2 was 
50nM.  The reaction was incubated in fluorimeter and warmed to 30oC.  Excitation was 
set at 425nm to excite ECFP and avoid excitation of EYFP, and readings were taken in 
0.2nm increments.  An initial reading was taken prior to ATP addition.  To initiate 
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reaction, ATP was added to a final concentration of 1 µM, a spinner was activated for 1 
minute, and the first reading taken at 2 minutes.  EYFP to ECFP ratios were calculated by 
dividing EYFP peak emission by ECFP peak emission.  Peak emissions were defined as 
an average intensity of EYFP between 524.6-525.4 nm and of ECFP between 474.6-
475.4 nm. 
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Chapter 4 
Exploring Dose-Response Effects of dMek1 and ROG 
on CD4/CD8 Lineage Determination Using Lentiviral 
Transgenesis 
 
4.1 Abstract 
 A double-positive thymocyte must make a decision to become either a CD4+ or 
CD8+ mature T cell during the differentiation phase of positive selection.  While it is 
clear that this choice is directed by the interaction of the T cell receptor with either MHC 
class I (CD8+) or class II (CD4+), the involvement of Ras/Erk MAP kinase signaling in 
this process is unclear.  In this chapter, we describe an application of a recently described 
method of transgenesis using lentiviral vectors in an effort to study the dose-effects of 
dMek1 expression in thymocytes in a single generation of mice.  We initially established 
a rough correlation of transgene expression and transgene copy number.  We were also 
able to show that the variegation in transgene expression seen in the initial report was 
stable, demonstrating the viability of our approach in studying the effects of transgenes 
on the development in the thymus.  Data from dMek1 mice suggested no effect in 
CD4/CD8 lineage determination by reducing Erk signaling.  These data, however, were 
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incomplete as we were unable to identify transgene expressing cells.  We expressed the 
repressor ROG in thymocytes and also observed no effect.  These results may be 
indicative of technical difficulties with this novel approach for studying lineage 
determination.  Future experiments should focus on trouble-shooting this technique by 
recapitulating results from previous studies. 
 
4.2 Background 
Coherent Ras/Erk signaling is crucial during the onset of positive selection of 
thymocytes (reviewed in [1]).  The role of this signaling pathway in CD4/CD8 lineage 
determination, however, remains unclear.  Experiments affecting TCR signaling through 
Lck have leant support to a strength-of-signal model [2, 3].  One study indicated 
calcineurin and Erk MAPK signaling in lineage commitment [4], although this study 
relied completely on pharmacological stimulation in culture rather than on a more 
physiological method.  There is also evidence that Erksem, a hypersensitive form of Erk2, 
increased CD4+ development, but the effect was modest [5].  To address this issue, we 
developed a system that would allow for genetic manipulation of the Ras/Erk pathway 
and study the dose-dependent effects of a dominant negative form of Mek1 (dMek1) on 
lineage determination (Figure 4-1).  Our aim was to utilize the relatively new technique 
of lentiviral transgenesis to create transgenic animals for analysis, as opposed to the 
canonical method of creating transgenic animals by pronuclear injection. 
Microinjection of foreign DNA into the male pronucleus of mouse zygotes is the 
standard and established method to make transgenic animals that was first introduced by 
Gordon and Ruddle [6].  A gene construct is introduced with a gene-of-interest (GOI)  
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Figure 4-1.  Experimental design for lentiviral transgenic analysis of CD4/CD8 
lineage determination.  AND+ or DO11.10+ embryos were harvested <24 hours after 
mating, and concentrated lentivirus was microinjected into the perivitelline space. 
Injected embryos were then implanted into a surrogate mother and allowed to litter. 
Transgenic mice were analyzed for transgene integration by southern blot of genomic 
DNA purified from tail tissue.  Thymii and/or spleens were harvested from selected mice 
between 4 and 6 weeks of age and were analyzed for dose-dependent lineage choice 
switch from CD4 SP to CD8 SP. 
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controlled by promoter/enhancer sequences.  Several copies of the gene (1-100) integrate 
into the genome, and the efficiency of integration and number of copies integrated are 
dependent on many factors.  Such factors include DNA concentration, construct size, 
timing of the injection, and how proficient the technician is with microinjection.  Several 
advancements have been made in an effort to fine tune this process for increased 
efficiency, but the overall process has changed little since its discovery.  The end result is 
the integration of the foreign DNA into the host genome.  Copy number alone, however, 
rarely correlates the gene expression level in founder mice.  The transgenic protein 
expressed in each founder is dependent on many factors, including copy number (more 
copies can sometimes decrease expression) and the specific site of integration [7].   
One cannot, therefore, deduce the level of protein expression solely by detecting 
the transgene copy number by southern blot of mouse genomic DNA.  To determine 
protein expression levels, each founder must be mated and a line established.  Some 
offspring would be used for analysis, while others would be mated to continue the 
established line.  This process is further lengthened by the fact that it is often necessary to 
use zygotes derived from the mating of two different mouse strains.  Backcrossing to 
establish a syngeneic line is considered complete at 14 generations, which takes over 2 
years assuming a 2-3 month generation time.  To determine a transgenic dose response, 
one would have to establish many different founders, analyze each individually for 
protein espression levels, and backcross each individual line to obtain syngeneic lines.  
The resources required for such a project are prohibitive.  Our lentiviral approach, 
however, allows for dose-dependent analysis of transgene expression in a single 
generation, decreasing time and monetary costs significantly. 
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Silencing of retroviral expression is a common problem in infection of stem cells.  
After initial infection and integration, gene expression is often quickly silenced by a 
combination of histone deacetylation, chromatin rearrangement, and CpG methylation [8, 
9].  Lentiviruses, however, are often less susceptible to similar silencing effects [10, 
11],and have been successfully implemented in the treatment of genetic disease [12].  
Recently, a novel method of creating transgenic animals has been described [13].  Using 
a self-inactivating (SIN) lentiviral vector coding for EGFP as the gene-of-interest, the 
authors were able to infect mouse and rat zygotes with a replication-incompetent virus.  
Under ubiquitin promoter control, EGFP was expressed in every tissue examined by the 
authors.  In addition, the authors were able to direct EGFP expression to specific tissues 
of transgenic animals.  The Lck proximal promoter was able to direct EGFP expression to 
thymocytes specifically.  Similarly, the myogenin promoter directed EGFP expression to 
skeletal muscle.  The authors also examined germ-line transmission and found that the 
viral transgene could indeed be transmitted to further generations. 
This novel method to create transgenic animals, however, does have a few 
shortcomings.  Traditionally, transgenesis is performed by intracellular injection of 
transgenic DNA.  Concatamers of the transgenic vector often integrate together, resulting 
in multiple copies of the transgene that are confined to one genomic locus.  Germ-line 
transmission of the transgene is stable because either all the copies of the transgene are 
passed on or none are.  Retroviral insertions, in contrast, occur randomly throughout the 
genome. The resulting germ-line transmission would be diluted over several generations.  
Another shortcoming is that mice expressing GFP under the Lck proximal promoter 
exhibit variegation in gene expression ([13], supplemental data).  The stability of this 
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variegation, however, was not explored by the authors and required our attention if this 
method were to be viable.  This topic is discussed later in this chapter. 
Although there are apparent pitfalls with using this system, there are specific 
advantages we sought to utilize.  Due to variations in the amount of concentrated virus 
delivered per injection and the statistical variability of infection, each embryo will 
receive a different number of transgene copies.  Given the random integration of the viral 
genome, there is likely a rough correlation between transgene copy number and actual 
protein expression.  Each pup in the resulting litter will have a different number of 
transgene copies, and therefore will harbor different levels of transgene expression.  Each 
litter will therefore not only give information for each individual transgenic mouse, but 
will also give us dose-dependence data as a whole.  This is clearly an advantage over 
attempting to establish several different transgenic lines by traditional transgenesis. 
To specifically study the role of the Ras/Erk cascade in CD4/CD8 lineage 
determination, we needed to use a transgenic TCR animal model.  A model already 
successfully used to study the role of Lck in lineage determination is the AND transgenic 
TCR [2].  This TCR is specific for a pigeon Cytochrome C peptide in the context of I-Ek 
and is MHC class II restricted, which under normal developmental conditions yields 
CD4+ T cells [14].  Importantly, the AND TCR is co-receptor independent, allowing for 
the characterization of functionally mature T cells in the absence of co-receptor binding 
[15, 16].  Our expectation, then, would be that we could drive the development of CD8+ 
T cells with dominant negative forms of Ras or Mek1 (dnRas or dMek1, respectively) in 
an AND TCR background if the Ras/Erk pathway plays a role in CD4/CD8 lineage 
determination. 
 92
 
4.3  Results and Discussion 
4.3.1  Reproduction of FLckGW mice 
 To verify the efficacy of lentiviral transgenesis and to familiarize ourselves with 
the technical aspects of making these mice, we began by reproducing a portion of the 
experiment described by Lois, et al. [13].  Being that our interests lay in the thymus, the 
most appropriate construct to use was the FLckGW construct, which coded for GFP 
expression under the Lck proximal promoter.  Lentivirus was packaged in the HEK-293 
cell line, concentrated by ultracentrifugation, and administered to newly fertilized 
C57Bl/6 embryos by perivitelline injection.  Progeny were analyzed by southern blot of 
genomic tail DNA to determine integration and estimate gene copy number.  Based on 
this analysis, three mice were chosen with 0, low, and high copy and analyzed for GFP 
expression in the thymus and spleen. 
 Genomic DNA was purified from tail tissue from each of the 18 progeny resulting 
from the FLckGW lentiviral infection of mouse embryos.  Each sample was digested by 
PstI restriction endonuclease, transferred to Hybond-N+ membrane, and probed with a 
radiolabeled DNA probe specific for a portion of GFP.  The results are shown in Figure 
4-2B.  It is apparent that each mouse received a different pattern and number of 
integrations, consistent with the previous report [13].  This was a key feature to using 
lentiviral transgenesis to study dose effects of dMek1 on lineage determination, as we 
expected variable gene expression in these mice.  Mouse PN681-1 (***), mouse PN681-5 
(**), and mouse PN684-13 (*) were used to analyze variation in gene expression as a 
corollary to gene copy number and to confirm variegation in transgene  
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 Figure 4-2.  The structure of the FLckGW construct and genomic analysis of
transgene integrations.  A)  The lentiviral construct FLckGW contains the HIV-1 flap,
followed by the Lck proximal promoter, enhanced GFP (EGFP), and the woodchuck
response element (WRE), flanked by long terminal repeats (LTR) at the 5’ end and a
truncated 3’ LTR (∆3’ LTR).  B)  Southern analysis of mice from injection panels PN681
and PN684 (indicated) and flanked by 1 kb DNA marker (M) and C57Bl/6 wild-type
(wt) as a negative control.  PN684-13(*NLC), PN681-5 (**low copy), and PN681-1
(***high copy) were analyzed further.  Transgene detection was by [32P]-radiolabeled
probe specific for EGFP.  The arrow indicates a non-specific band that was later
determined to be plasmid contamination. 
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expression. 
 Analysis of thymocytes revealed that GFP expression was indeed dependent on 
gene copy number (Figure 4-3).  The percentage of GFP+ cells in the entire thymic 
population was approximately double in the mouse PN681-1 (***) versus the mouse 
PN681-5 (**).  In addition, peak GFP fluorescence was higher in PN681-1 (***) 
thymocytes, indicating that not only does gene copy number affect the percentage of 
transgene expressing cells, but also affects the level of protein expression.  As expected, 
the normal littermate control (NLC) PN684-13 (***) that had received no transgene 
copies had no GFP-expressing cells.   
Both the GFP+ and GFP– population were analyzed for CD4 and CD8 surface 
expression.  This allowed us to determine whether the GFP– population was only DN 
cells that had not initiated expression off the Lck proximal promoter due to immaturity, 
or if this population was due to variegation in gene expression (Figure 4-3B).  
Percentages of DP and SP thymocytes were comparable in the two populations, 
indicating that some cells had indeed not initiated transgene expression, even though Lck 
expression driven by the Lck proximal promoter had been initiated.  The DN population 
was slightly higher in the GFP– population, likely due to a small number of cells that 
would potentially express the transgene, but had yet to initiate Lck proximal promoter-
directed expression.  It should be noted as well that presence of the transgene had no 
effect on normal development of the CD4 or CD8 T cell lineages, as seen in the SP 
compartment and in the periphery, discussed below. 
We also analyzed the peripheral T cell compartment by extracting lymphocytes 
from the spleen of each transgenic mouse (Figure 4-4).  These cells were stained for  
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 Figure 4-3.  Thymic analysis of 3 mice from injection panel PN681 for GFP 
expression.  A)  Live thymocytes from each mouse were analyzed for GFP expression 
by flow cytometry.  Gates indicate the percentage of GFP+ cells in each population.  B) 
CD4/CD8 analysis of cells gated on GFP expression, as indicated by GFP+ and GFP–. 
Percentages of DN, DP, and SP populations are indicated in the corner of each plot. 
Note that GFP expression has no effect on population percentages.
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TCRβ surface expression to distinguish them from other white blood cells that also 
inhabit the spleen.  As with thymocytes, peripheral T cells were analyzed for GFP 
expression and stained for CD4 and CD8.  GFP was found to be expressed in similar 
percentages of peripheral T cells as was found in thymocytes, and the level of 
fluorescence was also comparable.  The percentages of CD4 and CD8 T cells were 
comparable in the PN684-13 (NLC) and PN681-5 (low copy) in both the GFP+ and GFP– 
populations.  In the high copy number mouse PN681-1 (high copy), there seemed to be a 
skew in the percentage of CD8 T cells in the GFP+ population, suggesting that high-level 
transgene expression could cause non-specific effects.  This also could be due to an 
aberrant sample, but should be examined in future experiments.  Another odd finding was 
the presence of GFP+ T cells in the periphery.  Lck expression from the proximal Lck 
promoter is terminated during the DP→SP transition and is then directed by the distal 
Lck promoter in the SP and peripheral compartments [17, 18].  Other transgenic lines 
driven by the Lck proximal promoter have shown similar expression in mature cells [19, 
20].  It is possible that high GFP expression in mature T cells in FLckGW mice are a 
result of multiple integration sites, decreasing the ability of cells to silence a given locus. 
  
4.3.2  Variegation in lentiviral gene expression is stable 
To utilize lentiviral transgenesis as an effective tool to study signaling in 
thymocyte development, variegation in lentiviral gene expression seen in [13] must be 
stable.  Control of transgene expression is crucial, given the importance of different 
signaling molecules at developmental checkpoints.   Should expression of the transgene 
initiate at one developmental stage and be silenced at a later time, it could drastically  
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Figure 4-4.  Splenic analysis of 3 mice from injection panel PN681 for GFP
expression.  A)  Live splenocytes gated for TCRbhi expression were analyzed for GFP
expression by flow cytometry.  Gates indicate the percentage of GFP+ cells in each
population.  B)  CD4/CD8 analysis of cells gated on GFP expression, as indicated by
GFP+ and GFP-.  Percentages of DN, DP, and SP populations are indicated in the corner
of each plot.  Note that GFP expression has no effect on population percentages.
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affect the timing of development and the final developmental outcome of a given cell.  
Alternatively, if transgene expression were to be silenced past the developmental stage in 
which the tissue-specific promoter should be activated, it could have similar timing and 
outcome effects.  The resulting confusion would greatly decrease the validity of any data 
derived from or conclusions made about that experiment. 
To determine the stability of variegation we designed an experiment using 
reaggregate Fetal Thymic Organ Culture (RgFTOC) (Figure 4-5).  Self-inactivating (SIN) 
lentivirus coding for GFP under control of the Lck proximal promoter was expressed and 
packaged in HEK-293T cells and concentrated by ultracentrifugation.  C57Bl/6 mouse 
zygotes were harvested after fertilization, and concentrated lentivirus was delivered by 
sub-zonal injection with a micropipette.  Infected zygotes were implanted into surrogate 
mothers and day E14.5-E15.5 embryos were harvested.  Each fetal thymus was harvested 
separately, disassociated, and analyzed for GFP expression (Figure 4-6).  Lobes 
containing both GFP-negative (GFP–) and GFP-positive (GFP+) cells were collected and 
pooled. 
To reduce the possibility of sorting GFP– cells that had yet to initiate expression 
from the Lck proximal promoter, we decided to sort only cells from the DN3 and DN4 
populations.  Pooled thymocytes were stained with α-CD25 and α-CD44, conjugated to 
phycoerythrin (PE) and allophycocyanin (APC), respectively.  The CD25+/CD44– (DN3) 
and CD25–/CD44– (DN4) populations were sorted based on GFP expression.  The 
DN3/DN4/GFP+ and DN3/DN4/GFP– populations were then separately reaggregated 
with thymic stromal cells derived from treated E14.5 B6D2F1 fetal thymii, which had 
been depleted of thymocytes by treatment with the nucleotide analog 2’-deoxyguanosine.   
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Figure 4-5.  Experimental design to determine stability of variegation in transgene 
expression.  Transgenic E14.5 thymii were harvested from surrogate mother, and DN3 
and DN4 populations were sorted into GFP+ and GFP– populations.  Stromal cells from 
2’-deoxyguanosine-treated host lobes were dissociated and reaggregated with either 
GFP+ (labeled Tg+) or GFP– (labeled Tg–) cells sorted from transgenic lobes or left 
unseeded (stroma-only).  FTOC lobes were then analyzed at 7 and 14 days. 
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Figure 4-6.  GFP expression in individual fetal thymii from transgenic fetuses. 
Thymocytes from dissociated lobes #1, #2, #3, #7, #9, and #16 (red boxes) were chosen 
for the variegation experiment based on having >15% GFP+ cells.  These cells were 
pooled, sorted for DN3/DN4/EGFP+ and DN3/DN4/EGFP– populations, and used to seed 
RgFTOC.  Abbr.: green fluorescent protein (GFP), forward scatter (FSC). 
 101
This host strain is the F1 cross between C57Bl/6 and DBA2 strains and was chosen 
because any thymocytes not eliminated by 2’-deoxyguanosine treatment could be 
distinguished based on expression of different alleles of CD5 and H-2D. This distinction 
was key, given that any host thymocyte contamination of lobes would be perceived as 
negative for GFP expression in Tg+ lobes and confused as a decrease in viral gene 
expression.
Donor thymocytes were pure C57Bl/6 progeny and only express H-2b MHC 
haplotype and the CD5.2 allele.  B6D2F1 progeny express both H-2b and H-2d 
haplotypes, as well as CD5.1.  Day 7 fetal lobes were analyzed using an α-H-2Dd 
antibody, which failed to effectively distinguish H-2d+ from H-2b+ cells (data not shown).  
Due to the variability in specificity of antibodies to mouse alloantigens we tested an α-
CD5.1 antibody for the ability to distinguish C57Bl/6 and B6D2F1 thymocytes and 
compared it to the failed α-H-2Dd (Figure 4-7).  Thymocyte samples from C57Bl/6 and 
B6D2F1 mice were stained individually and in a 1:1 mixture with α-H-2Dd and α-CD5.1.  
In contrast to the α-H-2Dd antibody, α-CD5.1 could distinguish host cells from donor 
cells and was used for day 14 analysis. 
Although we were unable to distinguish donor and host thymocyte populations, 
we analyzed several day 7 lobes for GFP expression and CD4 and CD8 expression within 
the GFP+ and GFP– populations.  GFP expression was absent in stroma-only lobes, with 
the GFP– population in these lobes representing contaminating host thymocytes (Figure 
4-8).  High percentages of cells from the Tg+ lobes were GFP expressers, with a small but 
significant number of GFP– cells.  These were likely host contaminants, but may also 
have represented a population of transgenic donor thymocytes that had terminated GFP  
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 Figure 4-7.  C57Bl/6 and B6D2F1 thymocytes can be distinguished by a-CD5.1, but
not by α-H-2Dd.  C57Bl/6 thymocytes, B6D2F1 thymocytes, and a mixture of the two
were stained with α-CD5.1 and α-H-2Dd.  A)  The α-H-2Dd staining gives a much
smaller peak shift and cannot distinguish a 1:1 mixture of thymocytes.  B)  The α-CD5.1
staining gives distinctly separated peaks for C57Bl/6 and B6D2F1 thymocytes and can
distinguish the two populations in a 1:1 mixture.  α-CD5.1 was therefore used to
distinguish donor versus host in day 14 analysis. 
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Figure 4-8.  GFP analysis of day 7 RgFTOC lobes.  Each panel indicates the day 7 
GFP analysis of one RgFTOC lobe seeded either with no donor thymocytes (stroma-
only), GFP+ donor thymocytes (Tg+ lobes), or with GFP– donor thymocytes (Tg– lobes). 
Pink gates represent the percentage of GFP– cells within each lobe, and blue gates 
represent the percentage of GFP+ cells within each lobe.  The small percentage of GFP+
cells in the GFP– lobes may be due to slight contamination of cells that had very low 
GFP expression during the sorting phase of this experiment.  
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expression.  Lastly, each of the Tg– lobes contained cells that appeared in the GFP+ gate 
(Figure 4-8, blue boxes).  All of these cells had low GFP fluorescence and represented a 
small portion of the population.  These low expressers may have had too little 
intracellular GFP during the initial cell-sort and sorted as GFP– or may not have initiated 
transgene expressing despite entering the DN3 stage. 
 We stained day 7 FTOC samples with α-CD4 and α-CD8 fluorescent conjugates 
for CD4/CD8 analysis.  We analyzed the GFP– and GFP+ populations of each lobe 
separately by the gates established in Figure 4-8.  Percentages of DN, DP, and SP 
populations in the GFP– population from the Tg+ lobes were similar to that of the stroma-
only lobes and different than the Tg– lobes (Figure 4-9).  This would suggest that the 
GFP– cells in the Tg+ lobes were host cell contaminants, although confirmation of this 
was not possible until the day 14 analysis, discussed below.  CD4/CD8 analysis of the 
GFP+ population of Tg– lobes, however, correlated with percentages found in the Tg+ 
lobes, further indicating that these cells were donor thymocytes that had either initiated 
GFP expression after cell-sorting or were poor expressers at the time of sorting (Figure 4-
10). 
Day 14 analysis of Tg+ lobes showed that a high percentage of the GFP+ 
population was CD5.1– (Figure 4-11).  Conversely, the GFP– population was almost 
entirely CD5.1+ indicating that this population was made up of contaminating host 
thymocytes.  Two interesting findings were the existence of small populations of 
GFP+/CD5.1+ and GFP–/CD5.1–.  Theoretically, the transgenic thymocytes could be 
producing replication-competent virus and infecting the host cells.  This is unlikely, 
however, because the lentiviral construct we used is self-inactivating, and two separate 
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Figure 4-9.  CD4/CD8 analysis of the GFP– population from day 7 RgFTOC lobes. 
Each panel indicates the day 7 CD4/CD8 analysis of the GFP– population (pink gates in 
figure 4.8) from one RgFTOC lobe.  Percentages of DN, DP, and SP populations are 
indicated in the four quadrants of each panel.  Note that percentages of these populations 
were similar in the stroma-only lobes and Tg+ lobes, yet different in the Tg– lobes.  This 
indicated that the GFP– population in the Tg+ lobes was likely host thymocyte 
contamination. 
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Figure 4-10.  CD4/CD8 analysis of the GFP+ population from day 7 RgFTOC lobes. 
Each panel indicates the day 7 CD4/CD8 analysis of the GFP+ population (blue gates in 
figure 4.8) from one RgFTOC lobe.  Percentages of DN, DP, and SP populations are 
indicated in the four quadrants of each panel.  Similar percentages of these populations in 
both Tg+ and Tg– lobes indicated that they were likely derived from donor thymocytes. 
The presence of GFP+ cells in Tg– lobes could have been due to very low expression of 
GFP during initial sorting, or a small percentage of cells in the DN3 population that had 
not yet initiated expression from the Lck proximal promoter. 
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Figure 4-11.  Day 14 analysis of RgFTOC lobes for GFP expression and host 
contamination.  See next page for caption text. 
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igure 4-11 cont’d:  Each pair of panels represents an individual lobe with percentages 
for each gate indicated.  Stroma-only lobes showed a large percentage of CD5.1+ cells, 
indicating the presence of viable host thymocytes even after 2’-deoxyguanosine 
treatment.  Some of these cells were also CD5.1– and may represent some of the 
CD5.1– GFP– cells in Tg+ lobes.  The almost all CD5.1– cells were also in GFP+ in Tg+
lobes, suggesting that expression of the transgene was maintained once transcription was 
nitiated.  Conversely, most of the cells in the Tg– lobes remained GFP–, indicating that 
pontaneous transgene expression in DN3 or DN4 thymocytes that had not initiated 
ransgene transcription was a rare event.  
encoding of gag, pol, and env viral genes.  These cells have equivalent GFP fluorescence 
but only an intermediate fluorescence for CD5.1, as compared to host cells.  It is likely 
that these cells are a small portion of the GFP+ transgenic cells that are staining slightly 
for CD5.1, possibly due to cross-reactivity. 
Tg– lobes had a very small percentage of GFP+ cells, a majority of which were 
CD5.1 intermediate.  The GFP– population was mostly CD5.1–, but CD5.1+ host-cell 
contamination was evident.  The close grouping of the “GFP+” population at similar 
fluorescence values for both GFP and CD5.1 indicate a small population of 
autofluorescent cells, commonly found during RgFTOC analysis (G. Hernandez Hoyos, 
personal communication).  It is likely that these cells do not express GFP or CD5.1, but 
are broadly autofluorescent.  Those few cells that are not in this population could 
possibly be GFP+, indicating that cells initially sorted as GFP– had started expressing 
GFP.  Very few cells exhibit this, however, and may be examples of cells that were 
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sorted but had not yet initiated expression directed by the Lck proximal promoter. 
It can be concluded from this experiment that transgene expression is variegated, 
but relatively stable.  The onset of expression is consistent with Lck proximal promoter-
driven transgenes, although termination of expression is not, possibly due to the 
combination of multiple integration sites and the use of the minimal promoter.  While the 
ratio of expressing to non-expressing cells varies from animal to animal and seems to 
correlate with transgene copy number, the site of integration is also important for 
transgene expression (L. Yang, personal communication) and likely variegation.  An 
unforeseen advantage of variegation in transgene expression is the effective presence of a 
control population within each individual transgenic mouse.  Those cells that did not 
initiate transgene expression should develop normally and can be analyzed alongside 
thymocytes that express the transgene. 
 
4.3.3  Analysis of dMek1 and ROG expression in transgenic mice 
To distinguish thymocytes that had initiated transgene expression from those that 
had not, we added an internal ribosome entry site (IRES) followed by GFP downstream 
of the GOI in our lentiviral construct (Figure 4-12A).  The IRES-GFP we used was the 
non-attenuated variant of the IRES derived from the mouse stem cell virus (MSCV) 
promoter-based vector MIG [21].  We have had much success using MIG in our 
laboratory for coexpression of GOIs and GFP in thymocytes as well as in murine cell 
lines [22, 23].  The advantage of this construct is the identification of GOI-expressing 
cells by flow cytometry.  This was particularly important with this lentiviral system 
because of the variegated transgene expression.  Identification of the transgene-
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expressing population would be necessary to properly interpret results. The coexpression 
of GFP would allow us to easily identify transgene-expressing cells without having to 
perform intracellular staining, which would require us to kill the cells by fixation and 
permeabilization.  That would limit our ability to do ex-vivo analysis of the transgene 
expressing cells. 
The titer of IRES-GFP-containing virus was approximately 10-fold less than that 
of FLckGW virus, as tested in 16610D9 cells (data not shown).  As a result, infection of 
embryos was less efficient, and fewer integrations were apparent in transgenic mice that 
were infected with the IRES-containing construct.  We used mice expressing the 
DO11.10 transgenic TCR, another MHC class II-restricted TCR, for these experiments 
because the AND+/+-Rag2o mice had not yet been bred.  We infected DO11.10+ mouse 
embryos with virus containing the FLp(dMek1)IGW construct (Figure 4-12A).  Analysis 
of 4 FLp(dMek1)IGW mice with a differing number of integrations, as determined by 
southern blot (data not shown), revealed no discernable GFP+ populations (Figure 4-
12B).  There was a slight increase in the “GFP+” gated population that correlated with an 
increase in copy number, but could very well be coincidental.  An easily distinguishable 
GFP+ population would be required to identify transgene-expressing cells, and it is likely 
that the IRES is somehow rendered non-functional, as seen with other IRES-containing 
lentiviral transgenics (L. Yang, personal communication). 
We next examined the ability of PMA to stimulate Erk activation as an indirect 
measure of dMek1 repression (Figure 4-12C).  Thymocytes were stimulated with 1 nM 
PMA for 10 minutes, and pErk level was determined by intracellular staining.  Activation 
of Erk in mice positive for the lentiviral transgene was deficient in a manner correlating  
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Figure 4-12.  Analysis of FLp(dMek1)IGW mice in a DO11.10 TCR background. 
See next page for caption text. 
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Figure 4-12 cont’d:  A)  The FLp(dMek1)IGW was derived from FLckGW, containing 
dMek1 followed by an IRES sequence upstream of GFP.  B)  GFP expression in 
transgenic was not detectible by flow cytometry, even with high transgene copy.  C)  Erk 
activation was impaired in mice positive for the dMek1 transgene and particularly 
pronounced in the highest copy mouse.  D)  Decreased percentages of SP populations, 
increased DP percentages, and decreased percentages of TCRbhi cells indicated impaired 
positive selection in transgene positive mice, indicative of dMek1 activity.  There was no 
apparent increase in CD8 SPs at the expense of CD4 SPs, suggesting that dMek 
expression had no effect on lineage determination. 
to gene copy number. 
CD4/CD8 analysis of DO11.10+ thymocytes from these mice revealed a reduction 
in positive selection, but no apparent increase in CD8+ SP cells at the expense of the 
CD4+ SP population that would be consistent with a change in lineage choice (Figure 4-
12D).  This may indicate that while disruption of the Erk MAPK pathway affects survival 
and maturation, as has been shown [24, 25], it does not play a significant role in 
CD4/CD8 lineage determination.  This result may also be due to the DO11.10 TCR being 
a poor model for lineage decision studies, as seen in transgenic mice expressing a 
dominant negative form of Lck in a DO11.10 background that showed only a reduction in 
positive selection and no effect on lineage choice [26].  Should the latter be the case, it 
would be important to use a proven lineage choice model, such as the AND TCR [2], for 
these studies.  It should also be noted that the mouse with the highest copy number, 
LV1025-5, showed the smallest deficiency in positive selection, which is not consistent 
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with having the highest dMek1 transgene expression. 
Some of the data from this experiment revealed technical difficulties that should 
be pursued.  There is no apparent GFP expression off of the IRES sequence from within 
the lentiviral RNA transcript, and thus we were unable to use GFP fluorescence to 
identify the cells that were expressing dMek1 as well as the level of expression attained 
in those cells.  The only indication we had was an indirect measure of dMek1 repression 
by activation of Erk with pharmacological stimulation.  Intracellular staining of Mek is 
not efficient and not a viable option for determining transgene expressing cells (Figure 4-
13A).  We have produced a dMek1 construct with an N-terminal FLAG-tag and have 
successfully detected the epitope with intracellular staining using an α-FLAG antibody 
(Figure 4-13B).  In this manner we will be able to identify transgene-expressing cells, 
although this will limit our ability to use transgenic cells for ex vivo analysis because we 
must fix and permeabilize the cells for analysis.  Conditions for staining, however, have 
already been optimized as discussed in Chapter 2. 
The results from the dMek1-expressing transgenics indicate the possibility that 
the Erk MAPK pathway does not play a role in lineage determination, but experiments 
performed thus far are not conclusive.  We attempted to address this issue with a better 
candidate for lineage-decision involvement, Repressor of GATA (ROG) [27].  Our 
laboratory has recently shown the involvement of the GATA-3 transcription factor in the 
promotion of CD4+ lineage choice [23].  As its name implies, ROG is involved in 
GATA-3 repression and curbs the action of GATA transcription family members if 
overexpressed [23, 27].  Transgenic mice were generated with a construct containing 
ROG (FLp(ROG)IGW) in the DO11.10 TCR background.  CD4/CD8 analysis of ROG  
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 Figure 4-13.  FLAG-tagged proteins are detectable with intracellular staining,
whereas Mek 1/2 are not.  A)  α-Mek 1/2 staining of thymocytes from dMek1-positive
transgenic mice is ineffective at distinguishing transgene expressing cells.  B)  HEK-293
cells transfected with FLAG-tagged dMek1 are distinguishable by intracellular staining
with an α-FLAG antibody when compared to an untransfected population. 
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mice showed no change in lineage decision (Figure 4-14).  As with the dMek1 mice, we 
were unable to see GFP expression and we did not have a working protocol for ROG 
intracellular staining (data not shown).   
Failure to demonstrate any change in lineage determination with these two 
transgenic systems may be due to a technical difficulty in our approach.  It is possible 
that the DO11.10 TCR background is inadequate for these types of studies.  It is also 
imperative in future studies to be able to distinguish transgene-positive and transgene-
negative populations in order to appropriately analyze effect on lineage determination.  
While co-expression of GFP or any reporter off an IRES sequence does not seem to be 
plausible, we can most likely overcome this problem by intracellular staining of either the 
transgenic protein directly or an N-terminal FLAG-tag integrated into the transgene 
sequence. 
  
4.3.4  Establishing AND+/+-Rag2 KO mouse line 
AND+/+-Rag2o mice are no longer available for purchase, so we decided to 
establish the line through breeding.  To establish this line, we had to cross AND 
homozygotes and Basel-Rag2 null lines.  6 AND+/+ males were purchased from The 
Jackson Laboratory (B10.Cg-Tg(TcrAND)53Hed/J), and each was mated with 2 Basel-
Rag2o females.  The resulting AND+/--Rag2+/o F1 progeny were back-crossed with Basel-
Rag2o, taking care not to mate offspring from the same parental mating pair.  Initial 
screening of the F2 generations was done by tail bleed.  At the time of weaning (3-4 
weeks post-natal), each mouse had its tail cut, and 5-7 drops of blood were added to 
500µl of 1X PBS supplemented with heparin.  Blood cells were stained with fluorescent  
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 Figure 4-14.  Mice positive for the ROG transgene showed slight enhancement of
both the CD4 and CD8 lineages.  A)   Mice positive for the ROG transgene had slight
increases in both CD4 and CD8 SP percentages, inconsistent with previous data that
ROG reduced CD4 development.  The percentage of TCRbhi was also slightly increased
in ROG-Tg+ mice.  There was no apparent bias toward the CD8 lineage consistent with a
change in lineage determination.  Relative copy numbers were determined by southern
blot prior to analysis.   
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antibodies for the AND transgenic TCR and for B220, a B-cell marker.  The latter 
staining was done to detect the presence of B-cells, which would be indicative of a viable 
copy of the Rag2 gene. 
Stained blood cells were analyzed by flow cytometry.  Mice positive for the AND 
TCR and negative for a B220+ population were kept for further breeding.  All others were 
culled.  These mice were fixed for Rag2o locus and heterozygous for the AND TCR.  We 
mated these mice to each other in order to obtain AND TCR homozygotes.  Offspring 
were screened by tail bleeds as above, and 1 cm of tail tissue was collected and frozen for 
later analysis.  All mice were B220–, confirming that the Rag2o had been fixed.  Those 
mice that were AND– by blood screening were culled.  Mice that were positive for the 
AND TCR were analyzed further by Southern blot of genomic DNA extracted from tail 
tissue mentioned above. 
Southern blots were probed with DNA probes specific for the AND TCR 
transgene and Ets1 as a background loading control.  Data was obtained by densitometry 
of the AND and Ets1 bands and the AND signal was normalized to the Ets1 loading 
control (Figure 4-15A).  The normalized AND signals were compared to select 
candidates for homozygocity.  We expected that mice with two copies of the transgene 
would have approximately twice the normalized signal of heterozygous mice.  We found 
that several mice had significantly more signal than the others.  We chose these as 
homozygous candidates and used two males in a test-cross to validate that mice with 
double the signal were indeed homozygous.  To speed up our analysis, we decided to 
sacrifice pregnant females at E12 and harvest and analyze the embryos, rather than wait 
until they were born and old enough to obtain tissue without having to sacrifice  
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Figure 4-15.  Determination of homozygosity of the AND TCR gene in AND/Rag2o
mice.  A)  Signal from an AND southern analysis was quantitated and normalized to 
Ets1.  Each panel is representative of samples from a single gel.  Males with the strongest 
signal, 7287* and 7803*, were used for a test-cross with wild-type C57Bl/6 females. B) 
Genomic DNA was isolated from resultant test-cross embryos and PCR analysis was 
performed specifically for the AND TCR transgene.  19/20 embryos from the 7287 test-
cross and 10/10 embryos from the 7803 test-cross were positive for the AND transgene. 
It is possible that one negative from the 7287 test-cross was a false negative due to the 
apparent absence of the primer band. 
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them.  It is important to note that some of the embryos were not as developed as others, 
and their small size made them very difficult to harvest. 
Embryos were harvested into individual wells of a 96-well plate and genomic 
DNA was extracted from each.  These samples were analyzed by PCR for the AND TCR 
transgene (Figure 4-15B).  19 out of 20 of the progeny from the #7287 test-cross and 10 
out of 10 of the progeny from the #7803 test-cross were positive.  While one would 
expect all of the progeny to be positive by PCR if males #7287 and #7803 were truly 
homozygous for the AND TCR transgene, it is likely that the one negative sample was 
either a problem with the PCR reaction or that the “embryo” from that sample was 
actually maternal tissue harvested accidentally.  Based on these results, we concluded that 
the males that were tested were homozygous for the AND TCR transgene and that mice 
with similar signal by southern blot were also homozygous.  These mice were then used 
as founders for our AND+/+-Rag2o line. 
 
4.4  Future Directions 
 We were unable to obtain clear results from the transgenic mice we produced.  To 
truly get a sense of whether or not this system can work for our purposes our next step 
would be to recapitulate the experiment done with a dominant-negative form of Lck in 
the AND TCR background [2].  Should this be successful, it would not only reconfirm 
the results seen in that paper, but also show that this method of transgenesis is viable for 
studying lineage determination.  This would, of course, hinge on the ability to stain for 
Lck by intracellular staining or would require the addition of a FLAG-tag to distinguish 
transgene-expressing cells. 
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 Once it has been established that our system will work, we would then re-examine 
the involvement of dMek1 as well as dominant-negative Ras (dnRas).  dnRas has been 
shown to have a more widespread effect on positive selection than dMek1 [25] and could 
present a bifurcation point for signals originating at the TCR.  Transcription factor 
expression and regulation can also be explored, such as GATA family transcription 
factors and other factors known to be involved in positive selection [23, 28-30].  Such 
targets could include Ets family transcription factors, Egr1, Id3, and E-box proteins.   
 
4.5  Concluding Remarks 
 Our approach using lentiviral transgenesis to study gene dosage effects in 
transgenic mice could potentially be used as a time and money saving tool for creating 
and analyzing transgenics.  That said, it is quite time and cost inefficient at its current 
stage and requires further optimizations.  Still, the prospect of being able to potentially 
create a wide range of transgene expressors in a single litter is appealing, since creating 
many lines of mice by canonical transgenesis is time consuming and costly. 
 
4.6 Materials and Methods  
4.6.1  Cell staining and flow cytometry 
   Cell surface staining was performed in 100 µl P4F for 15 minutes on ice.  One 
million cells were resuspended in 50 µl of P4F and 50 µl of P4F containing indicated 
antibody.  Antibodies were used at the following final concentrations:  α-CD8-APC at 
1:100 (eBiosciences), α-CD4-CyC at 1:200 (eBiosciences), α-H-2Dd at 1:50 (BD 
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Pharmingen), and α-CD5.1-PE at 1:200 (BD Pharmingen).  Samples were spun at 500 x 
g for 3 minutes and washed twice with P4F.  After the final wash, cells were resuspended 
in a minimum of 250 µl of P4F and then transferred to FACS tubes.  Flow cytometry was 
conducted on either a FACScalibur or a FACScan (Becton Dickinson) and analyzed 
using Flowjo software (TreeStar).  Intracellular staining was performed as described in 
Chapter 2.  All unlabeled axes are based on a log-scale relative fluorescence. 
 
4.6.2  Production of Lentivirus 
 293T-HEK cells were plated on three 10 cm tissue culture dishes (Falcon) at a 
concentration of 4 x 106 cells/dish in DMEM culture medium (Invitrogen).  Cells were 
transfected by CaPO3 precipitation 24 hours after initial plating with 4 µg each of:  1) 
plasmid containing GOI (FlckGW, FLp(ROG)IGW, or FLp(dMek)IGW), 2) delta 8.9 
plasmid, and 3) VSVg plasmid.  Precipitates were removed after 4 hours, washed with 1 
x PBS, and 10 ml fresh DMEM was added to each plate.  Supernatants were collected 
after 48 hours, pooled together, and filtered through a 0.45 µm syringe filter.  Lentivirus 
was concentrated by ultracentrifugation by spinning samples at 4oC for 90 minutes at 
25,000 rpm in a Beckman SW-28 rotor.  Supernatant was carefully removed and 100 µl 
of 1 x PBS was added to the pellet.  Pellet was incubated overnight at 4oC, resuspended 
by pippeting, and supplied to the mouse facility for perivitteline injection of mouse 
embryos. 
 
4.6.3  Reaggregate fetal thymic organ culture 
Fetal thymic organ culture was performed as described [23].  Transgenic 
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thymocytes were sorted as GFP+ and GFP– populations as indicated and lobes were 
reaggregated with these populations.  Lobes were analyzed at 7 and 14 days post-
reaggregation. 
 
4.6.4  Southern blotting of genomic DNA 
10µg of tail-derived genomic DNA was digested with 20 units (U) of Pst I for 2 
hours at 37oC.  An additional 20 U of Pst I was added to each reaction and incubated for 
2 additional hours.  Samples were loaded on a 0.8% agarose gel supplemented with 
200ng/ml ethidium bromide and run at 50 volts overnight.  Gels were visualized under 
ultraviolet light.  Gels were treated with 0.25M HCl, followed by 0.4M NaOH and 
transferred to Hybond N+ (Amersham) membrane by capillary transfer.  Prehybridization 
was performed for 1 hour at 65oC in Church’s buffer supplemented with 100µg/ml 
salmon sperm DNA.  GFP-specific radiolabeled DNA probe was then added to the 
prehybridization buffer and incubated overnight at 65oC.  Membranes were twice washed 
in 2x SSC buffer for 1 hour at 65oC and exposed to a phosphoscreen.  Phosphoscreens 
were scanned on a Storm 860 (Molecular Dynamics) and analyzed using ImageQuant 
software. 
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Chapter 5 
A General Approach to Detect Protein Expression In 
Vivo Using Fluorescent Puromycin Conjugates 
 
This chapter has previously appeared as:  Starck SR, Green HM, Alberola-Ila J, 
Roberts RW: A general approach to detect protein expression in vivo using 
fluorescent puromycin conjugates. Chem Biol 2004, 11(7):999-1008.  The 
formatting of this paper has been adapted to this thesis, while content remains unchanged. 
 
H. M. Green’s contribution to this paper is as follows:  in conjunction with S. R. Starck, 
the design and execution of experiments contributing to Figures 5-4, 5-5, 5-6, and 5-7 as 
well as comments to the manuscript with regard to these experiments. 
 
5.1  Abstract 
Understanding the expression of known and unknown gene products represents 
one of the key challenges in the post-genomic world.  Here, we have developed a new 
class of reagents to examine protein expression in vivo that does not require transfection, 
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radiolabeling, or the prior choice of a candidate gene.  To do this, we constructed a series 
of puromycin conjugates bearing various fluorescent and biotin moieties.  These 
compounds are readily incorporated into expressed protein products in cell lysates in 
vitro and efficiently cross cell membranes to function in protein synthesis in vivo as 
indicated by flow cytometry, selective enrichment studies, and western analysis.  Overall, 
this work demonstrates that fluorescent-puromycin conjugates offer a general means to 
examine protein expression in vivo.   
 
5.2  Introduction 
Complete sequencing of the human genome [1, 2] shows that less than 50% of the 
putative gene transcripts correspond to known proteins. A complete understanding of the 
proteome awaits the identification of thousands of unassigned gene products and 
assignment of their role in signaling cascades [3], membrane trafficking [4], apoptosis 
[5], and other cellular processes. Currently, there are large-scale techniques to study 
cellular protein levels indirectly using DNA and mRNA arrays [6].  However, these 
techniques do not directly monitor the level of protein synthesis.  Methods to directly 
monitor protein expression in vivo are extremely useful, particularly in the study of 
higher organisms with many different cell and tissue types.  
Currently, protein expression is studied using pulse-labeling with a radioactive 
tracer or by transformation with fluorescent reporters based on the green fluorescent 
protein (GFP) and mutants (BFP, CFP, and YFP) [7].  Pulse-labeling experiments 
typically require the cell(s) to be destroyed and are not amenable to microscopy 
experiments with simultaneous protein synthesis detection.  Genetically encoded GFP 
 
 129
mutants and fusion proteins have seen broad biological applications including study of 
Ca2+ localization [8], protein tyrosine kinase activity [9], and mRNA trafficking and 
protein synthesis localization in cultured neurons [10, 11].  However, the use of GFP-
based constructs is limited to cells that can be efficiently transfected.  Additionally, DNA 
transfection protocols often require several days to produce cells yielding robust GFP-
based fluorescent signals and also inundate the protein synthesis machinery with a non-
native transcript due to the use of strong upstream promoters.  Finally, transfection-based 
strategies generally require choice of a particular candidate gene product.    
We reasoned that puromycin-based reagents might provide a general means to 
examine protein expression.  Puromycin is a structural analogue of aminoacylated-tRNA 
(aa-tRNA) and participates in peptide-bond formation with the nascent polypeptide chain 
(Figure 5-1A) [12, 13].  Previously, various puromycin derivatives of the form X-dC-
puromycin have been examined and shown to be functional during in vitro translation 
experiments [14-17].  In principle, a fluorescent or biotinylated variant of puromycin 
should be functional in protein synthesis in vivo if it is able to enter cells in a non-
destructive fashion (Figure 5-1B).  In this way, selective labeling of newly synthesized 
proteins would enable direct monitoring of protein expression and provide the potential 
for both spatial and temporal resolution.  Here, we demonstrate that a variety of 
puromycin conjugates can be used as detectors of protein synthesis in live cells.  This 
work shows that puromycin conjugates can easily enter cells and covalently label newly 
synthesized proteins, enabling direct detection of protein expression in vivo. 
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Figure 5-1.  (A) Puromycin (P) participates in peptide bond formation with the nascent 
polypeptide chain.  (B) Puromycin-dye conjugates, of the form X-dC-puromycin where 
X = fluorescein (F), are also active in translation and become covalently linked to 
protein. 
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5.3  Results 
5.3.1  Design of puromycin conjugates 
To label newly synthesized proteins, our puromycin conjugates would have to 
satisfy three general criteria:  1) functionality in peptide bond formation, 2) cell 
permeability, and 3) ready detection in a cellular or biochemical context.  In addressing 
the first issue, it had been previously shown that puromycin derivatives bearing 
substitutions directly off the 5’ OH functioned poorly in vitro (e.g., biotin-puromycin 
IC50 = 54 µM) [17], whereas conjugates with the general form X-dC-puromycin (e.g., 
biotin-dC-puromycin) were substantially more effective (IC50 = 11 µM) [17].  We 
therefore chose to design molecules by varying the substituents appended to dC-
puromycin (Figure 5-2A).   
In order to facilitate cellular entry and detection, we considered a number of 
factors including:  1) type and position of the label, 2) the linker between the label and 
dC-puromycin, 3) background fluorescence properties, and 4) membrane permeability 
including net charge and hydrophobicity.  We then designed and synthesized various dC-
puromycin conjugates to address these issues systematically.  The first series of 
puromycin conjugates (1, 3, 4, 6, 8; Figure 5-2A) either contain fluorescent dyes 
(compounds 1 and 4), biotin (compound 6), or both (compounds 3 and 8).  Two different 
fluorescent dyes were utilized (Cy5 and fluorescein) to provide detection at a range of 
emissions.  Biotin labels were introduced to enable detection via western blot analysis or 
affinity purification.  We also prepared a series of compounds (2, 5, 7, 9; Figure 5-2A), 
which lack the 3’-amino acid moiety to serve as negative controls.   
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Figure 5-2.  (A) Structure of puromycin conjugates and negative control conjugates.  (B) 
Structure of phosphonate-based puromycin and negative control conjugates. 
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A second series of conjugates with a phosphonate linkage between dC and 
puromycin was prepared to examine whether reduction of charge would enhance cell 
membrane solubility and facilitate cellular entry (Figure 5-2B). Three compounds (10, 
11, 12; Figure 5-2B) were constructed bearing fluorescein (10, F2P-Me), biotin (11, B2P-
Me), or the hydrophobic dimethoxytrityl group (DMT) and fluorescein (12, DMT-F2P-
Me).  A DMT-bearing fluorescein-dC-dA conjugate (DMT-F2A-Me) served as a 
negative control (13; Figure 5-2B).  The DMT group was added to gauge whether the 
addition of a hydrophobic group would further enhance entry into cells.   
 
5.3.2  Analysis of puromycin-conjugate activity in vitro 
We began our analysis by examining the activity of each of our conjugates in 
vitro for their ability to inhibit protein translation.  Previously, we had used this activity 
assay to measure the IC50 for various puromycin conjugates [17] and analogues [18], as 
well as demonstrate a direct relationship between the IC50 and the efficiency of protein 
labeling [17].  High resolution tricine-SDS gel data corresponding to a typical IC50 
determination is shown for Cy52P (1) and Cy52A (2) (Figure 5-3A). Using this approach, 
we measured IC50 values for the compounds in Figure 5-2A and 5-2B (Figure 5-3B).  
Generally, the activity of conjugates with the form X-dC-puromycin falls over a fairly 
narrow range in vitro, with IC50 values ranging from ~4 to ~30 µM (Table 1).  Also, 
control conjugates that lack the amino acid moiety, e.g., Cy52A (2) and BF2A (9), show 
little ability to inhibit protein synthesis even at high concentrations.  
 We next wished to confirm that our puromycin conjugates could become 
covalently attached to protein in vitro.  To do this, we translated globin mRNA in the 
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presence of increasing concentrations of FB2P (3), a conjugate containing fluorescein 
and biotin moieties (Figure 5-3C).  Next, the concentration-dependent incorporation of 
FB2P was analyzed using neutravidin affinity chromatography of these same translation 
reactions (Figure 5-3D).  These data indicate that puromycin conjugates are incorporated 
efficiently over a broad concentration range ranging from 2- to 3-fold below the IC50 to 
well above it.  Thus labeling is possible even at concentrations where protein synthesis is 
not greatly inhibited.  
These observations support the development of a broad range of puromycin-based 
reagents for two reasons.  First, compounds of the form X-dC-puromycin appear tolerant 
to a wide variety of substitutions, including molecules containing more than one 
detection handle (e.g., BF2P and FB2P).  Interestingly, even the methyl phosphonate 
versions (F2P-Me, 10; B2P-Me, 11; DMT-F2P-Me, 12) showed good levels of in vitro 
activity.  Second, the IC50 values indicate that even modest concentrations of each of 
these reagents in the low micromolar range will be sufficient to achieve good levels of 
protein labeling.  This is because our data here (Table 1, Figure 5-3), as well as previous 
data [17, 18], demonstrate that protein labeling is achieved at or below the IC50 value.   
Thus, these in vitro translation and protein labeling assays provide a starting 
concentration range for analysis in live cells. 
 
5.3.3  Analysis of puromycin-conjugate activity in vivo 
In order to analyze the activity of puromycin conjugates in vivo, we needed to 
choose both an appropriate cell line and an appropriate quantitation and detection 
scheme.  While microscopy is a powerful means to analyze individual cells and small  
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Figure 5-3.  In vitro activity analysis for various puromycin conjugates.  (A) Tricine-
SDS-PAGE analysis of globin translation reactions in the presence of Cy52P (1) (top) 
and Cy52A (2) (bottom):  Lane 1, no template and no conjugate; lane 2, globin alone; 
lanes 3-10, conjugate concentrations from 0.5 µM to 120 µM.  (B) Percent of globin 
translation relative to the no conjugate control for compounds 1, 2, 3, 4, 6, 8, 10, 11, and 
12.  (C) Tricine-SDS-PAGE analysis of globin translation reactions incubated with 
increasing concentrations of FB2P (3):   Lane 1, no template, no conjugate; lane 2, 
globin alone; lane 3, 7 µM; lane 4, 35 µM; lane 5, 70 µM; lane 6, 140 µM; and lane 7, 
210 µM.  (D) Neutravidin-purified globin-FB2P complexes from translation reactions in 
(C). 
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Table 5-1.  The concentration of puromycin conjugate required for 50% inhibition 
of globin translation (IC50).* 
Puromycin conjugate               IC50 (µM) 
(1)    Cy52P     3.8 
(2)    Cy52A     >100 
(3)    FB2P     24 
(4)    F2P           22 
(6)    B2P     15 
(8)    BF2P     5.8 
(10)  F2P-Me      25 
(11)  B2P-Me      16 
(12)  DMT-F2P-Me    29 
*In replicate experiments, the standard error is <5%. 
 
sections of tissue, we wished to perform experiments where thousands to millions of cells 
could be examined for protein labeling.  We therefore chose flow cytometry as our 
primary means to analyze uptake and incorporation of our conjugates.  In addition to 
providing a quantitative measure of fluorescence and cell size, flow cytometry methods 
enable live cells and dead cells to be readily distinguished [19].  We chose the 
mammalian thymocyte D9 cell line (16610D9) [20] for our experiment for four reasons:  
1) they have relatively uniform size and shape, 2) they do not aggregate, making single 
cell detection possible, 3) they are suspension cells, which allow for ready growth in 
culture with subsequent acquisition of a large number of single cell readings using flow 
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cytometry, and 4) they are amenable to routine infection techniques to introduce 
selectable markers and GFP-based tags. 
We began by comparing the concentration and time dependence of labeling with 
F2P (4) and the negative control conjugate F2A (5) (Figure 5-4A,B).  For F2P, 
progressively increased fluorescence is seen with increasing time and the greatest 
enhancement is seen after the 24 h incubation at both 5 µM and 25 µM of the conjugate 
(Figure 5-4A,B).  At both concentrations, a substantial population of live cells is detected 
and demonstrates up to 4-fold enhanced fluorescence relative to the F2A control 
molecule.  Longer incubation (48 hours) in the presence of F2P eventually kills the 
majority of cells at both concentrations tested.  In contrast, the background fluorescence 
from F2A reaches a maximum of ~101 units after a 7 h incubation for both 5 and 25 µM 
incubations (Figure 5-4A,B), and F2A has no apparent effect on cell viability.  The 
fluorescence enhancement beyond 101 units for cells treated with F2P is consistent with 
C-terminal protein labeling by the fluorescein-puromycin conjugate.  These experiments 
also suggest that there is an optimum concentration and incubation time for labeling 
expressed proteins without killing the cells.     
We next wanted to examine the relative level of fluorescence enhancement for a 
series of conjugates.  To do this, a uniform population of D9 cells was split into separate 
containers, each containing identical concentrations of a different puromycin conjugate, 
incubated for 24 hours, and analyzed by flow cytometry with a live-cell gate as before 
(Figure 5-4C).  In this series, DMT-F2P-Me (12) gives the strongest enhancement, and 
the rank order of compounds follows DMT-F2P-Me (12) > FB2P (3) ~ BF2P (8) > F2P 
(4) ~ F2P-Me (10) > FP.  The IC50 values for all the compounds with the exception of FP   
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Figure 5-4.  Analysis of puromycin conjugate activity in 16610D9 thymocyte cells. 
Dose-response analysis of 16610D9 thymocyte cells treated with F2P or F2A at (A) 5 
µM and (B) 25 µM.  Incubation times are 1 (   ), 7 (   ), 24 (   ), and 48 h (   ).  Untreated 
cells incubated for 1h are indicated with (   ).  Cells were analyzed using a flow cytometer 
and gated on a live cell population according to forward and side scatter plots.  (C) Flow 
cytometry analysis of untreated cells (   ); Fluorescein-puromycin, FP (   ); F2P, 4 (   ); 
F2P-Me, 10 (   ); FB2P, 1 (   ); BF2P, 8 (   ); DMT-F2P-Me, 12 (   ).  Cells were 
incubated for 24 hour with puromycin conjugates at 50 µM.  Analysis was performed 
using flow cytometry using a live cell gate as in A and B.  (D) Epi-fluorescence 
microcopy of D9 cells treated with DMT-F2P-Me (25 µM) with 200 X magnification. 
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(IC50 = 120 µM [17]) are relatively similar, while addition of the DMT group in 
compound (12) would be expected to confer increased hydrophobicity and membrane 
permeability.  Compounds containing a phosphate (F2P (4)) or a methylphosphonate 
(F2P-Me (10)) bridging the puromycin and dC residue show little difference in IC50 
values (Figure 5-3B, Table 1) and in vivo labeling (Figure 5-4C), arguing that charge at 
this position does not play a key role in either the activity as a substrate or entry into the 
cell. The poor IC50 for FP in vitro [17] correlates with the small fluorescence 
enhancement seen for this compound in vivo (Figure 5-4C).  Epi-fluorescence 
microscopy confirms that the conjugate DMT-F2P-Me (12) readily enters and labels D9 
cells brightly (Figure 5-4D).  
Following these experiments, we next wished to confirm that two of the best 
compounds, BF2P (8) and DMT-F2P-Me (12), also showed fluorescence enhancement in 
vivo relative to control molecules containing only a terminal adenosine. Indeed, 
comparison of cells treated with BF2P (8) versus BF2A (9) (Figure 5-5A) and DMT-
F2P-Me (12) versus DMT-F2A-Me (13) (Figure 5-5B) indicates that compounds bearing 
the terminal puromycin moiety show a 3- to 4-fold fluorescence enhancement as 
compared with the control molecules.  This shift in fluorescence is consistent with 
labeling protein during rounds of translation.  Overall, the combination of our in vitro and 
in vivo observations is consistent with the notion that the overall fluorescence 
enhancement reflects both the efficacy and the cellular permeability of the compounds. 
 
5.3.4  Mechanism of puromycin conjugate activity in vivo 
We next wished to demonstrate that the puromycin conjugates we had constructed  
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Figure 5-5.  Fluorescence shift analysis for puromycin conjugates versus negative 
control molecules in 16610D9 thymocyte cells.  (A) Untreated cells (   ); BF2A, 9 (   ); 
BF2P, 8  (   ).  (B) Untreated cells (   ); DMT-F2A-Me, 13 (   ); DMT-F2P-Me, 12 (   ). 
Analysis was performed using flow cytometry using a live cell gate as described for 
Figure 5. 
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were acting in vivo by the same mechanism as puromycin itself.  Puromycin can be used 
as a selection agent in mammalian cell culture to kill cells that lack the resistance gene 
encoding puromycin N-acetyl-transferase (PAC) [21].  This enzyme N-acetylates the 
reactive amine on puromycin and blocks its ability to participate in peptide bond 
formation [22, 23].  In a mixed population of cells, those that lack a vector expressing 
PAC can be selectively killed by long incubations (≥ 48 hours) with puromycin, leaving 
only vector-containing cells alive.  Previously, we showed that chemical acylation 
inactivates puromycin-mediated translation inhibition in vitro [17].  Thus, we wished to 
see if the D9 cells bearing PAC would be resistant to killing (and thus enriched in the 
mixed population) by long incubations with puromycin itself or our puromycin 
conjugates in vivo.   
Foreign genes can be inserted into D9 cells by infection with a viral vector (see 
Experimental Procedures).  Vectors that express GFP provide a straightforward means to 
measure the fraction of cells that become infected and a direct means to monitor any 
vector-mediated enrichment.  We infected D9 cells with a viral vector driven by a mouse 
stem cell virus promoter (MSCV) containing an internal ribosome entry site (IRES) 
upstream from enhanced green fluorescent protein (EGFP) referred to as MIG (MIG = 
MSCV-IRES-GFP; Figure 5-6) [24].  MIG expresses GFP so that infection efficiency 
can be monitored by GFP fluorescence (Figure 5-6).  A second vector containing the 
PAC gene was also constructed (MIGPAC; Figure 5-6) and results in a bicistronic mRNA 
in which both PAC and GFP can be translated (Figure 5-6).   
Flow cytometry was used to examine both the infection efficiency and confirm 
the ability to perform puromycin-based enrichment.  After infection with the MIG or 
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MIGPAC vectors, 5.0 % and 4.3 % of the D9 cells were infected and alive based on GFP 
expression, respectively (Figure 5-6B; upper panels).  In both cases, the other 95% of the 
cells showed no GFP-based signal.  Puromycin was then added to both MIG and MIGPAC 
infected cells followed by incubation for 48 hours at 37ºC.  For MIG infected cells, 
puromycin results in almost complete killing of both GFP-positive and GFP-negative 
cells (Figure 5-6B; lower, left panel).  For MIGPAC infected cells, puromycin selectively 
kills only those cells lacking GFP, such that after 48 hours the population is totally 
dominated by GFP-positive cells (94%) (Figure 5-6B; lower, right panel).  Enrichment of 
GFP-positive cells occurs because they express the PAC resistance protein that acylates 
puromycin, rendering it inactive.  These experiments demonstrate that puromycin 
acylation is sufficient to rescue cells from puromycin toxicity and that N-blocked 
puromycin is non-toxic to D9 cells.  The selective enrichment of PAC-expressing cells 
argues that puromycin exerts its effect on D9 cells by acting on the translation apparatus 
in vivo.  
We next wished to examine if B2P (6) could act in a biochemically similar 
fashion as puromycin itself.  As with puromycin, flow cytometry indicated that long 
exposures of B2P (6) kills the vast majority of the cells infected with MIG (Figure 5-6C; 
bottom, left panel), while B2A (7), a control molecule lacking the amino acid, had no 
effect (Figure 5-6C; middle, left panel).  Importantly, cells infected with MIGPAC show 
selective enrichment when incubated with B2P (6) (Figure 5-6C; bottom, right panel), 
while B2A shows no change in GFP-positive and negative populations (Figure 5-6C; 
middle, right panel).  These experiments are fully consistent with B2P (6) acting by the 
same mechanism as puromycin itself.  Further, these data also provide the first 
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Figure 5-6.  Mechanism of action of puromycin and puromycin conjugates in 16610D9 
thymocyte cells infected with (A) MIG and MIGPAC constructs.  (B) Cells infected with 
MIG are sensitive to puromycin action but cells infected with MIGPAC are resistant to 
puromycin. (C) Cells infected with MIG or MIGPAC were treated with biotinylated-
puromycin conjugates B2A (7) and B2P (6).  
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 demonstration that PAC can act on puromycin conjugates bearing 5’-extensions in vivo. 
In line with this conclusion, two other puromycin conjugates show similar activity 
with B2P.  We examined a Cy5-bearing conjugate Cy52P (1) and compared its action 
with an analogous control molecule, Cy52A (2), using both MIG and MIGPAC infected 
cells.  Cy5 provides a useful spectroscopic handle in this context because its red-shifted 
fluorescence allows the emission of the conjugate to be unambiguously separated from 
that of GFP.  As with B2P versus B2A, MIG-infected cells were insensitive to Cy52A, 
while long exposure of Cy52P killed both GFP-positive and negative populations, since 
they lacked the PAC resistance determinant (data not shown).  Cy52P also selectively 
enriched MIGPAC infected cells from 4.3 % to 90 % (data not shown).  Additionally, B2P-
Me (11) also resulted in selective enrichment of MIGPAC-bearing cells and had similar 
potency with B2P (6) (data not shown).  Taken together, these data support the idea that 
our various X-dC-puromycin conjugates act by the same mechanism as puromycin in 
vivo and that conjugates lacking the 3’-amino acid moiety have no effect. 
 
5.3.5  Western blot analysis of puromycin conjugate labeling in live cells 
Action of puromycin and our conjugates should result in proteins bearing these 
compounds at their C-terminus in vivo.  We chose to use Western blot analysis of cellular 
lysates to examine if incorporation occurred in vivo and to compare the resulting signal 
with our control conjugates.  Cells were incubated with either BF2P (8) or the control 
molecule BF2A (9) washed, and a whole-cell lysate was prepared for each sample (see 
Experimental Procedures).  Proteins were run on a SDS-PAGE gel and transferred to 
nitrocellulose.  Equal protein loading was confirmed in each lane using Ponceau S (data 
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not shown).  The Ponceau S stain was rinsed away and the blot was probed with an anti-
fluorescein antibody to detect any fluorescein-conjugated protein containing BF2P or 
BF2A.  Cells treated with BF2P (Figure 5-7; lane 2) show good levels of incorporation in 
this assay, while lanes with cells alone (lane 1), cells treated with BF2A (lane 3), or 
anisomycin (lane 4) show essentially no signal (Figure 5-7).  The Western-blot analysis 
of BF2P thus shows good correlation with flow cytometry data and is consistent with a 
model where puromycin conjugates are stably incorporated into proteins in vivo during 
protein synthesis.    
 
5.4  Discussion 
In the present study, we developed a technique to detect protein synthesis in live 
cells that does not require gene transfection or radiolabeling.  Our strategy thus provides 
an important potential alternative to these methods for studying protein expression in 
vivo.  Generally, a great diversity of reagents of the class X-dC-puromycin, where X can 
be one or two fluorescent or affinity tags, can be constructed and show good activity in 
protein synthesis in vitro and in vivo.   These reagents all appear to act by the same basic 
mechanism, entering the ribosomal peptidyl transferase site during translation, followed 
by covalent attachment to proteins being actively synthesized.  Ribosome entry and 
attachment occurs predominantly at a few discrete sites in the open reading frame 
including the stop codon, rather than at every position in the chain [17, 25].  Previous 
work also demonstrates that, over a 50-fold concentration range that brackets the IC50, the 
length of truncated products is the same and that shorter products are favored as the 
conjugate concentration is increased substantially.  
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Figure 5-7. Western analysis of 16610D9 thymocyte cells treated with a puromycin 
conjugate and analyzed using an α-fluorescein antibody:  Lane 1, untreated cells; lane 2, 
BF2P, 8 (25 µM); lane 3, BF2A, 9 (25 µM); and, lane4, anisomycin (250 ng/mL). 
Ponceau S stain was used to confirm equal protein loading.  BF2P-conjugated protein is 
seen at many molecular weights indicating that the conjugate could target all translating 
ribosomes. 
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Despite the intermediate size of these molecules (1163 to 1730 Da), all the conjugates 
appear to be competent to enter the D9 suspension tissue culture cells used here and to act 
at modest concentrations (5 – 25 µM).  Experiments with other mammalian and insect 
cell types support the idea that the ability of these compounds to cross membranes and 
act in protein synthesis is a general phenomenon (W. B. Smith, E. Schuman, B. Hay, 
unpublished observations).  All of the conjugates we have examined show a significant 
and measurable shift in the fluorescence intensity of live cells as compared to the control 
conjugates.  Western analysis and selective enrichment studies support the idea that this 
shift is due to the specific covalent attachment of the conjugates to nascent proteins 
during translation.  Demonstration that affinity tags may be inserted into expressed 
proteins in vivo provides the future opportunity to examine protein expression in response 
to various cellular stimuli and subsequent identification of the individual polypeptides 
through a combination of affinity purification and mass spectrometry-based sequence 
analysis.   
In the short term (~24 hours), these compounds are non-toxic based on the 
proportion of live cells seen in our flow cytometry experiments.  The robust labeling and 
signal to noise we observe thus makes these compounds useful for a great diversity of 
cell, tissue, and organism-level experiments.  The long-term toxicity of the present set of 
compounds may provide some limitations for their use.  In that context, non-toxic 
variants that can be photoactivated or presented as pro-drugs may provide useful paths 
for future conjugate development.  The general class of compounds described here should 
therefore serve as useful cell biology tools to evaluate in vivo protein synthesis in areas 
such as nuclear protein synthesis [26, 27], neuron dentritic protein synthesis [10], 
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dendritic cell aggresome-like induced structures (DALIS) [28], and other novel proteome 
functions. 
 
5.5  Significance 
Existing methods to study in vivo protein synthesis generally require choice of a 
candidate gene, radioactivity, or the destruction of cells.  To overcome these limitations, 
we have developed a new class of reagents that enable detection of protein synthesis in 
live cells using fluorescent and biotinylated puromycin conjugates.  These reagents, of 
the general form X-dC-puromycin, are active in vitro and in vivo and provide a non-toxic 
alternative for the study of protein synthesis in live cells.  A wide variety of detection 
moieties appears to be accommodated at the X-position allowing for facile custom 
reagent design and development.  Initial in vitro studies correlate the function of our 
compounds in peptide bond formation during protein synthesis.  Subsequent in vivo 
experiments in a mouse thymocyte cell line demonstrate the usefulness of these 
molecules as indicators of protein synthesis in live cells.  Selective enrichment studies 
with several conjugates as well as western analysis demonstrate that these compounds all 
label protein in cells by the same general mechanism, which is attachment to nascent 
proteins during translation.  The present results thus provide evidence that puromycin 
conjugates may serve as an alternative to existing tools to elucidate the proteome.  
 
5.6  Experimental Procedures 
5.6.1  Materials 
L-Puromycin hydrochloride, rabbit globin mRNA, and carboxypeptidase Y (CPY) 
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were obtained from Sigma Chemical Co. (St. Louis, MO).   Rabbit reticulocyte Red 
Nova® lysate was purchased from Novagen (Madison, WI).  L-[35S]methionine 
([35S]Met) (1175 Ci/mmol) was obtained from NEN Life Science Products (Boston, 
MA).  Immunopure® immobilized Neutravidin-agarose was from Pierce (Rockford, IL).  
GF/A glass microfiber filters were from Whatman.  
 
5.6.2  Puromycin conjugates  
Puromycin conjugates were synthesized using standard phosphoramidite 
chemistry at the California Institute of Technology oligonucleotide synthesis facility.  
Puromycin-CPG was obtained from Glen Research (Sterling, VA).  Oligonucleotides 
were synthesized with the 5’-trityl intact, desalted via OPC cartridge chromatography 
(Glen Research) (DNA oligonucleotides only), cleaved, and evaporated to dryness.  5’-
Biotin phosphoramidite, Biotin phosphoramidite, 5’-Fluorescein phosphoramidite, 6-
Fluorescein phosphoramidite (Glen Research) were used to make the biotin- and dye-
puromycin conjugates.  Ac-dC-Me-phosphonamidite (Glen Research) was used to 
prepare the phosphonate puromycin conjugates.  The dried samples were resuspended 
and desalted on Sephadex G-10 (Sigma).  Puromycin, puromycin-conjugate, and control 
molecule concentrations were determined with the following extinction coefficients (M-
1cm-1):  puromycin (ε260 = 11,790; in H2O); B2P and B2P-Me (ε260= 19,100; in H2O); 
F2P, F2P-Me, DMT-F2P-Me, FB2P, BF2P, F2A, and BF2A (ε491= 66,000; in 1X PBS); 
Cy52P and Cy52A (ε650= 250,000; in 1X PBS). 
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5.6.3  In vitro potency determination for puromycin conjugates 
Translation reactions containing [35S]Met were mixed in batch on ice and added 
in aliquots to microcentrifuge tubes containing an appropriate amount of puromycin-
conjugate (or control molecule) dried in vacuo.  Typically, a 20 µl translation mixture 
consisted of 0.8 µL of 2.5 M KCl, 0.4 µL of 25 mM MgOAc, and 1.6 µL of 12.5X 
translation mixture without methionine, (25 mM dithiothreitol (DTT), 250 mM HEPES 
(pH 7.6), 100 mM creatine phosphate, and 312.5 µM of 19 amino acids, except 
methionine), 3.6 µL of nuclease-free water, 0.6 µL (6.1 µCi) of [35S]Met (1175 
Ci/mmol), 8 µL of Red Nova nuclease-treated lysate, and 5 µL of 0.05 µg/µL globin 
mRNA.  Inhibitor, lysate preparation (including all components except template) and 
globin mRNA were mixed simultaneously and incubated at 30ºC for 60 min.  Each 
reaction (2 µL) was combined with 8 µL of tricine loading buffer (80 mM Tris-Cl (pH 
6.8), 200 mM DTT, 24% (v/v) glycerol, 8% sodium dodecyl sulfate (SDS), and 0.02 % 
(w/v) Coomassie blue G-250), heated to 90 ºC for 5 min, and applied entirely to a 4% 
stacking portion of a 15% tricine-SDS-polyacrylamide gel containing 20% (v/v) glycerol 
[29] (30 mA for 1h, 30 min).  Gels were fixed in 10% acetic acid (v/v) and 50% (v/v) 
methanol, dried, exposed overnight on a PhosphorImager screen, and analyzed using a 
Storm PhosphorImager (Molecular Dynamics).  
 
5.6.4  Neutravidin capture of in vitro translated protein-puromycin-conjugate 
products 
Neutravidin-agarose [50% slurry (v/v)] was washed 3 times with 1X PBS + 0.1% 
Tween-20 and resuspended in 1 mL of 1X PBS + 0.1% Tween-20.  To 200 µL of this 
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suspension, 12 L of the reaction lysate and 0.8 mL of 1X PBS + Tween-20 were added.  
The samples were rotated at 4 ºC for 3 h and washed with 1X PBS + Tween-20 until the 
cpm of [35S]Met were <500 in the wash.  The amount of immobilized [35S]Met-protein-
puromycin conjugate was determined by scintillation counting of the Neutravidin-agarose 
beads. 
 
5.6.5  Preparation of MIGPAC infected 16610D9 cells 
The PAC gene was cloned into MIG using BgII and EcoRI restriction sites to 
yield MIGPAC.  293T-HEK fibroblasts (American Tissue Culture Collection) were co-
transfected with pECL-Eco [30] and MIG or MIGPAC by calcium phosphate precipitation.  
After 12 hours, the precipitate was removed, cells were washed once with PBS, and 4 mL 
of fresh complete Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
fetal calf serum (FCS).  Viral supernatant was removed 24 hours later and used in 
infection of 16610D9 cells.  One million D9 cells were spin-infected with 0.4 mL of viral 
supernatant suplemented with 5µg/ml Polybrene (Sigma-Aldrich).   
 
5.6.6  Enrichment of GFP(+) 16610D9 cells using puromycin and puromycin 
conjugates 
16610D9 cells infected with either MIG of MIGPAC were cultured in RPMI media 
with 10% FBS and grown at 37 ºC in a humidified atmosphere with 5% CO2.  For each 
experiment, 16610D9 cells (0.25 x 106/well) were added to 24-well microtiter plates 
along with puromycin, puromycin-conjugate, and control molecules dissolved in the 
minimum amount of either media or PBS.  After a 48 h incubation, the cells were washed 
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twice in 2 mL PBS + 4% FCS and resuspended in PBS + 4% FCS supplemented with 2% 
formaldehyde along with incubation at 37 ºC for 10 min.  Flow cytometry was carried out 
on a Beckman FACScabilur Flow Cytometer. 
 
5.6.7  Detection of protein synthesis events in vivo using flow cytometry 
16610D9 cells (0.5 million mL-1) were combined with the various puromycin 
conjugates and control molecules resuspended in the minimum volume of PBS or media 
as described above.  After a 24 h incubation, the cells were washed twice in 2 mL PBS + 
4% FCS and resuspended in PBS + 4% FCS supplemented with 2% formaldehyde 
followed by incubation at 37 ºC for 10 minutes or used directly after washing for 
immediate flow cytometry analysis. 
 
5.6.8  Western analysis of 16610D9 cells treated with puromycin conjugates  
Cells were prepared as described above, except as indicated anisomycin was 
added to a final concentration of 250 µg mL-1, and washed twice in PBS.  Live cell 
number was determined using trypan blue exclusion dye, and each sample was adjusted 
to contain an equal number of live cells.  Cell pellets were resuspended in 2X lysis buffer 
(100 mM β-glycerophosphate, 3 mM EGTA, 2 mM EDTA, 0.2 mM sodium-
orthovanadate, 2 mM DTT, 20 µg/ml aprotinin, 20 µg/ml leupeptin, 50 µg/ml trypsin 
inhibitor, and 4 µg/ml pepstatin, and 1% Triton X-100) and incubated on ice for 30 
minutes.  Cell debris was removed by centrifugation at 20,000 x g for 30 minutes.  Cell 
lysate was combined with SDS loading buffer (0.12 M Tris-Cl (pH 6.8), 20% glycerol, 
4% (w/v) SDS, 2% (v/v) β-mercaptoethanol, and 0.001% bromophenol blue) and heated 
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at 90ºC for 10 minutes.  Samples were applied entirely to a 4% stacking portion of a 10% 
glycine-SDS-polyacrylamide gel (30 mA for 1h, 30 min).  Protein was transferred using 
standard Western transfer techniques, and the blot was probed with an anti-fluorescein 
antibody followed by an anti-rabbit-horseradish peroxidase conjugate (Pierce chemicals).  
The chemiluminescence reaction was carried out using the ECL PLUS Western Blotting 
Detection System (Amersham Biosciences). 
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